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1 Introduction
1.1 Opioid receptors
Opium has been known to relieve pain and alter mood since the advent of recorded
history (Gourlay, 2005). To date, opiates such as morphine are still the best analgesic
choice in the treatment of chronic and serious pain, such as cancer pain. However, their
extensive and long-term use is limited due to the development of opiate tolerance and
dependence. In addition, drug treatment can lead to drug abuse. Opiate drugs mediate their
physiological effects by binding to opioid receptors, which are also activated by
endogenously produced opioid neuropeptides (von Zastrow, 2004). Under the tremendous
efforts of the past years, we now understand mechanisms of opioid receptor signal
transmission in considerable detail. However, a definitive mechanism for opioid receptor
regulation, especially in the complex physiological circumstance of intact nervous system,
is still far from clear.
Figure 1.1. Structure of opioid receptors (modified from LaForge et al., 2000). Opioid receptor has
a central common core made of seven transmembrane helices connected by three intracellular and three
extracellular loops. The differences in N-terminal and C-terminal length for each receptor type are
shown.
Three independent reports on the identification of opioid receptors in 1973 (Pert and
Snyder, 1973; Simon et al., 1973; Terenius, 1973) marked the advent of a new era of the
opioid research. 20 years later, genes encoding three well-defined or “classical” types of
the opioid receptors, µ-, d- and k-opioid receptors, were cloned (Kieffer et al., 1992; Evans
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et al., 1992; Chen et al., 1993a; Minami et al., 1993; Fukuda et al., 1993; Li et al., 1993;
Meng et al., 1993; Yasuda et al., 1993; Wang et al., 1993).
Sequence analysis of these cloned opioid receptors revealed that they belong to the
superfamily of G protein-coupled receptors (GPCRs) and the subfamily of rhodopsin
receptors. As shown in Figure 1.1, the µ-, d- and k-opioid receptors have the putative
seven domains of 20-25 hydrophobic residues that form a-helices and span the plasma
membrane, an extracellular N-terminus, three extracellular loops, three intracellular loops
and an intracellular C-terminal tail (Evans et al., 1992; Kieffer et al., 1992; Chen et al.,
1993a; Fukuda et al., 1993; Li et al., 1993; Meng et al., 1993; Yasuda et al., 1993;
Waldhoer et al., 2004). These receptors are about 60% identical to each other, with the
greatest homology found in the transmembrane domains (73–76%) and intracellular loops
(86–100%). The lowest homology in amino acid sequence is found in the N-terminus
(9–10%), extracellular loops (14–72%), and the C-terminus (14–20%) (Chen et al., 1993b;
Law et al., 2000b).
Figure 1.2. Different amino acid sequence between rat MOR1 and MOR1B.
Numerous pharmacological studies have suggested subtypes of the µ-opioid receptor
(MOR1) and studies have raised the possibility that some of these may reflect splice
variants of the MOR1 gene (Wolozin and Pasternak, 1981; Pasternak, 1993; Pasternak and
Standifer, 1995). Two MOR1 variants, MOR1A and MOR1B, were identified shortly after
the initial cloning of MOR1 (Bare et al., 1994; Zimprich et al., 1995). MOR1 and MOR1B
differ at the C-terminus as shown in Figure 1.2. Thereafter, additional MOR1 splice
variants such as MOR1C, D, E and F were identified (Pan et al., 1999, 2000). All these
splice variants are identical in the first 386 amino acids. Though MOR1 and its splice
variants are derived from the same gene, and exhibit similar binding properties, they differ
in their functional properties and regional distributions (Schulz et al., 1998; Koch et al.,
1998; Pan et al., 1999, 2000; Abbadie et al., 2000; Bolan et al., 2004). Recently, more
carboxyl-terminal splice variants of the µ-opioid receptor were continually identified and
characterized (Pasternak et al., 2004; Pan et al., 2005).
The µ-opioid receptor (MOR1) mediates the action of most clinically important
opiate drugs, e.g. morphine, as well as drugs of abuse such as heroin (Matthes et al., 1996;
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Kieffer, 1999; Kieffer and Gaveriaux-Ruff, 2002). MOR1 is thought to be responsible for
opioid analgesic effects, and for unwanted effects, e.g. respiratory depression, euphoria,
sedation, tolerance and dependence.
1.2 Functional activities of opioid receptors
Stimulation of opioid receptors by the binding of specific ligands activates Gi/o
proteins, as a result of which the Ga subunit exchanges its GDP for GTP. G protein thus
dissociates from the receptor and both Ga and Gbg dimer carry the signal to their effectors,
which may be enzymes and/or ion channels.
Generally, stimulation of opioid receptors inhibits adenylate cyclase (AC), activates
inwardly rectifying potassium channels and inhibits voltage-sensitive calcium channels.
All result in decreased neuronal excitability and inhibition of neurotransmission (see Law
et al., 2000b and Williams et al., 2001 for reviews).
1.3 Intracellular trafficking of opioid receptors
Similar to other GPCRs, agonist binding to opioid receptors is followed by receptor
phosphorylation, which is mediated by G protein-coupled receptor kinases (GRKs)
(Kovoor et al., 1997; Pak et al., 1997; Wolf et al., 1999; Deng et al., 2000; Wang, 2000;
Law et al., 2000b; Schulz et al., 2004) and second messenger-regulated protein kinases,
such as Ca2+/calmodulin-dependent kinase II (Mestek et al., 1995; Koch et al., 1997, 2000;
Brüggemann et al., 2000) and mitogen activated protein (MAP) kinase (Polakiewicz et al.,
1998; Schulz and Höllt., 1998; Schmidt et al., 2000). The binding of b-arrestins to
phosphorylated receptors leads to receptor uncoupling from G-proteins, which in turn
causes receptor desensitization. In addition, b-arrestins bind to both the clathrin heavy
chain and the b2-adaptin subunit of heterotetromeric AP-2 adaptor complex, and target the
receptors to clathrin-coated pits, thereby linking the receptors to endocytic membranes.
The coordinated interaction of both clathrin and AP-2 with b-arrestins is necessary for
heptahelical receptor internalization via clathrin-coated pits (Goodman et al., 1996, 1997;
Gurevich and Benovic, 1997; Krupnick and Benovic, 1998; Laporte et al., 1999, 2000;
Ferguson, 2001; Claing et al., 2002; Pierce et al., 2002). Once the plasma membrane is
invaginated, GTPase dynamin wraps around and constricts the necks upon GTP hydrolysis,
thus vesiculation occurs. These vesicles soon shed their clathrin coats and become early
endosomes. The ligands and receptors are separated in an acidified perinuclear
compartment. Dissociation of b-arrestins also occurs. Cytosolic phosphatases may
dephosphorylate the receptors. The ligands are degraded while the receptors are either
recycled to the plasma membrane for resensitization or degraded in the lysosomes for
down-regulation (see Law and Loh, 1999; Ferguson, 2001; Williams et al., 2001; Claing et
al., 2002; Pierce et al., 2002; von Zastrow, 2003; Mousavi et al., 2004 for reviews).
The processes of agonist-induced intracellular trafficking of opioid receptors are
diagrammed in Figure 1.3.
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Figure 1.3. Typical pathways of opioid receptor trafficking.
1.3.1 Role of phosphorylation in the regulation of opioid receptor internalization
As shown above, one of the first events following receptor stimulation is the
recruitment of G protein-coupled receptor kinases (GRKs) to the plasma membrane and
receptor phosphorylation. GRK-mediated receptor phosphorylation enhances the
interaction between receptors and b-arrestins.
MOR1 is phosphorylated at a low level in the absence of agonist, and receptor
phosphorylation is significantly enhanced in the presence of etorphine or DAMGO (Arden
et al., 1995; Whistler et al., 1999). Morphine was observed to promote phosphorylation of
MOR1 to a lesser extent than opioid peptides and certain other alkaloid agonists (Arden et
al., 1995; Yu et al., 1997; Zhang et al., 1998). Consistent with these findings, etorphine or
DAMGO promotes rapid internalization of MOR1, whereas morphine fails to promote
significant receptor internalization. However, over-expression of GRK2 enables morphine
to promote rapid phosphorylation and internalization of MOR1 (Zhang et al., 1998). The
absence of agonist-induced phosphorylation by the mutation of putative phosphorylation
sites to alanine completely blocks or significantly attenuates the agonist-induced µ-opioid
receptor internalization (El Kouhen et al., 2001; Schulz et al., 2004). The rapid
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internalization of the d-opioid receptor (DOR1) is totally blocked in the presence of
heparin, an inhibitor of GRKs (Hasbi et al., 2000).
1.3.2 Post-endocytic sorting of internalized receptors
Some internalized GPCRs are dephosphorylated in sorting endosomes and recycled
rapidly to the cell surface, while others are sent to lysosomes for degradation. Trafficking
of GPCRs to lysosomes requires specific sorting events involving ubiquitin-dependent or -
independent interactions of receptors with cytoplasmic sorting proteins (Marchese and
Benovic, 2001; Tanowitz and Von Zastrow, 2002; Whistler et al., 2002; Shih et al., 2002).
MOR1 and DOR1 differ significantly in their intracellular sorting. The internalized
DOR1 is mainly targeted to lysosomes for degradation, whereas MOR1 and its spliced
variants have distinct properties to recycle back to the cell surface upon agonist treatment
(Koch et al., 1998, 2001; Wolf et al., 1999; Ko et al., 1999; Tsao and von Zastrow, 2000;
Wang et al., 2003; Tanowitz and von Zastrow, 2003; Marie et al., 2003). The role of the
carboxyl tail in directing opioid receptor trafficking has been established (Afify et al.,
1998; Kouhen et al., 2000; Koch et al., 1998, 2001; El Kouhen et al., 2001; Wang et al.,
2003). Recently, GASP (G protein-coupled receptor-associated sorting protein), was
identified as a candidate of lysosomal sorting protein, which binds strongly to the DOR1
carboxyl tail, and plays a key role in modulating DOR1 endocytic sorting to lysosomes
(Whistler et al., 2002).
Recycling of internalized opioid receptors to the plasma membrane is associated
with dephosphorylation of receptors (Tsao and von Zastrow, 2001). The efficient recycling
of opioid receptors requires a specific sequence that is conserved in the carboxyl tail of
MOR1 but is absent in DOR1. The MOR-derived endocytic recycling sequence (MRS)
distinguishes the endocytic trafficking of MOR1 from that of DOR1 (Tanowitz and von
Zastrow, 2003). However, this finding cannot explain why MOR1B (a splice variant of
MOR1) without this MRS shows faster recycling compared with MOR1 (Koch et al.,
1998). Thus, additional domains of MOR1 might exist to control the regulation of µ-opioid
receptor recycling.
The regulation by which opioid receptors are “sorted” between divergent recycling
and degradative pathways after receptor internalization is of particular interest due to its
importance on cell signaling and opiate responsiveness after long-term exposure to opiate
drugs.
1.4 Down-regulation of opioid receptors
Down-regulation is characterized by a decrease in the total number of receptors in a
cell, and is caused by long-term exposure to agonists for hours or days; recovery from
down-regulation is slow. From a physiological viewpoint, it is probably rare that a cell is
exposed continuously to opioids, since efficient mechanisms exist to remove them from the
extracellular fluid. However, down-regulation may occur under pathological circumstances
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and long-term administration of opiate drugs. Opioid receptor down-regulation may result
from a proteolytic degradation of internalized receptors and/or a decrease of newly
synthesized receptors.
Receptor internalization is considered as the first step in the down-regulation of
opioid receptors after chronic exposure to agonists. Trafficking of internalized receptors to
lysosomes promotes proteolytic degradation. In HEK293 cells, the rapid morphine-induced
endocytosis of MOR1D and MOR1E permits receptor down-regulation. In contrast, the
lack of morphine-induced internalization of MOR1 and MOR1C prevents receptor down-
regulation (Koch et al., 2001).
The observed decrease in the mRNA level of the opioid receptors after chronic
agonist treatment is suggested to be due to changes in the intracellular cAMP level (Kraus
et al., 1995; Kim et al., 1995). The cAMP dependent PKA has been shown to
phosphorylate CRE binding protein (CREB) and thereby to enhance receptor transcription.
Promoter analysis of rat MOR1 revealed that an increase of intracellular cAMP level by
forskolin enhances promoter activity in transfected SH SY5Y cells, whereas DAMGO by
inhibiting cAMP formation decreases transcription driven by MOR1 promoter (Kraus et
al., 1995).
In theory, down-regulation of opioid receptors would lead to tolerance by reducing
the number of functional receptors. Previous studies showed that µ-opioid receptor
downregulation contributes to opioid tolerance in vivo (Stafford et al., 2001). In fact, in
vitro, opioid receptor downregulation has been reported following chronic agonist
treatment (Law et al., 1983; Puttfarcken and Cox, 1989; Zadina et al., 1993, 1994; Yabaluri
and Medzihradsky, 1997). However, opioid receptors in brain have been reported to
decrease, increase or remain unchanged following chronic administration of agonists (for
reviews, see Liu and Anand, 2001; Harrison et al., 1998). Furthermore, the time course of
receptor down-regulation observed in cultured cells fails to match the time course of the
development of tolerance in vivo. Thus, it appears unlikely that receptor down-regulation
is solely responsible for the development of opioid tolerance.
1.5 Desensitization of opioid receptors
The early events of signaling by GPCRs are usually rapidly attenuated by receptor
desensitization (Lohse, 1993; Freedman and Lefkowitz, 1996), which reduces the ability of
receptors to modulate second messengers (Law et al., 1983; Nomura et al., 1994; Mestek et
al., 1995). Desensitization is a complicated process in receptor regulation, which can be
regulated as a consequence of multiple processes of receptor uncoupling, trafficking,
down-regulation, and so on.
An important component of receptor desensitization, which occurs within seconds to
minutes of receptor activation, is uncoupling of the activated receptor from its G-protein by
receptor phosphorylation. The phosphorylation facilitates the subsequent binding of b-
arrestin, which acts as a damper for further signaling by preventing further G-protein
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coupling (Böhm et al., 1997; Yu et al., 1997; Bohn et al., 1999, 2004; Law et al., 2000b;
Kohout et al., 2001; Ahn et al., 2003). In mice lacking b-arrestin 2, MOR1 remains
coupled with G-protein, and its desensitization does not occur even after chronic morphine
treatment (Bohn et al., 2000). The absence of agonist-induced phosphorylation by the
mutation of putative phosphorylation sites to alanine completely blocks or significantly
attenuates the agonist-induced receptor desensitization (Deng et al., 2000; Wang et al.,
2002; Schulz et al., 2004). The enhanced phosphorylation of MOR1 has been correlated
with the desensitization of MOR1 in thalamus of rats chronically treated with morphine
(Deng et al., 2001). Over-expression of GRK2 increases agonist-induced receptor
phosphorylation and promotes MOR1 desensitization (Zhang et al., 1998). However,
phosphorylation and b -arrestins do not appear to be necessary in all cases for
desensitization to occur in neurons and some test cell models (Kovoor et al., 1997;
Capeyrou et al., 1997; Cheng et al., 1998; Law and Loh, 1999; Williams et al., 2001),
implying that mechanisms other than receptor phosphorylation and the subsequent
interaction with b-arrestin mediating receptor desensitization exist.
The ability of cells to respond to opioids requires the presence of opioid receptors at
cell surface, where they can interact with agonists in the extracellular fluid. After receptor
internalization, the dephosphorylation and subsequent recycling of receptors back to the
plasma membrane therefore contribute to a reversal of the desensitized receptor state
(resensitization), which partially counteracts the receptor desensitization (Böhm et al.,
1997; Wolf et al., 1999; Hasbi et al., 2000). A MOR1 mutant, MOR363D, which does not
recycle after internalization, was observed to desensitize faster than that of wild type
MOR1 upon agonist activation (Qiu et al., 2003). The block of recycling pathway by
monensin, which traps internalized receptors within endosomes, enhances receptor
desensitization (Koch et al., 1998; 2004; Law et al., 2000a). Consistent with this, agonists
that could promote rapid receptor internalization and recycling lead to less receptor
desensitization (Koch et al., 2005).
1.6 Adenylate cyclase superactivation
Early studies revealed that opioids acutely inhibit AC activity in NG108-15 cells.
Later it has been shown that in the continued presence of morphine, there is an
upregulation of AC activity (Sharma et al., 1975). The phenomenon that chronic opiate
treatment followed by opiate withdrawal leads to enhanced forskolin-stimulated AC
activity and cAMP accumulation, has been termed AC superactivation. This has been
considered as a cellular hallmark of opiate withdrawal (Bohn et al., 2000; Fin and Whistler,
2001). Mechanisms that are responsible for AC superactivation are still controversially
discussed (for review, see Liu and Anand, 2001).
AC superactivation, originally observed in several cell lines and many types of
neurons, has been suggested to represent a general means of cellular adaptation to the
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activation of inhibitory receptors, and to play a role in the development of opiate tolerance
and dependence (Childers, 1991; Self and Nestler, 1995; Avidor-Reiss et al., 1995, 1996;
Nestler and Aghajanian, 1997; Williams et al., 2001; Liu and Anand, 2001; Fin and
Whistler, 2001; Johnston and Watts, 2003).
1.7 Opiate tolerance and dependence
Morphine and other opioids are used and abused for their analgesic and rewarding
properties. Tolerance to these effects, as well as physical and psychological dependence,
develops over hours/days to weeks. Tolerance is a decrease in responsiveness manifested
as a loss of response to a given dose of an agonist, or the requirement for an increased dose
to achieve the original effect. Dependence is a different phenomenon, much more difficult
to define and measure, which involves two separate components, namely physical and
psychological dependence. Physical dependence is associated with a physiological
withdrawal syndrome (or abstinence syndrome), manifesting as extreme restlessness and
distress accompanied by a strong craving for drugs. Re-administration of morphine rapidly
abolishes the abstinence syndrome. Drug users who are no longer physically dependent can
still show psychological dependence and relapse.
It is increasingly evident that opiate-induced tolerance and dependence occur at
multi-levels in the nervous system, beginning with regulation of opioid receptors
themselves and extending to a complex network of direct and indirect modifications of
“downstream” signaling machinery. Traditional mechanisms thought to underlie opiate
tolerance and dependence include receptor phosphorylation, G-protein uncoupling,
receptor down-regulation, desensitization, AC superactivation, the amount of effector
proteins or the capacity of an effector to be regulated by opioid receptors (reviewed in
Nestler and Aghajanian, 1997; Lefkowitz, 1998; Liu and Anand, 2001; Ferguson, 2001;
Von Zastrow et al., 2003; Bailey and Connor, 2005). Despite the delineation of many of the
physiological, biochemical, and molecular biological sequelae of persistent exposure to
opioids, elucidation of the biochemical underpinnings of tolerance and dependence
formation remains elusive.
1.8 Membrane glycoprotein M6 and its family
Using a monoclonal antibody, called M6 (Lagenaur et al., 1992), Yan and
collaborators (1993) identified two distinct membrane glycoprotein M6 (designated M6a
and M6b). M6a is one of the neuronal surface molecules in the central nervous system
(CNS) (Lagenaur et al., 1992; Yan et al., 1993). As shown in Figure 1.4B, at the amino
acid level, M6a is 54% identical with M6b, and shows greater homology to DM20 (42%)
than to proteolipid protein (PLP) (Yan et al., 1993; Olinsky et al., 1996; Mukobata et al.,
2002). DM20 differs from PLP by an internal deletion of 35-amino acid residues (116-150)
from the major hydrophilic domain in the intracellular loop of PLP (Nave et al., 1987;
Macklin et al., 1987; Simons et al., 1987).
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A.
B.
Figure 1.4. A. Proposed structural model of PLP/DM20 family. Members of the PLP/DM20 family
are tetraspan proteins, with four transmembrane domains, and with the NH2 and COOH termini both
located on the cytoplasmic face of the membrane. B. Alignment of mouse M6a, M6b and DM20
amino acid sequences. Analyzed by the program of “Multiple Sequence Alignment” in
http://workbench.sdsc.edu. Green amino acids (AA) represent identical sequence in these three
molecules, and red AA represents identical sequence in at least two molecules. The AA residues were
numbered on the right, respectively. Blue and gray regions represent transmembrane domains of M6a
and DM20, respectively (Mukobata et al., 2002; Greer and Lees, 2002).
The identification of M6a and M6b indicated the formation of a new gene family, the
PLP/DM20 family (Yan et al., 1993). Later, new members of this family, DMa, DMb, DMg
(Kitagawa et al. 1993) and Rhombex-29 (Shimokawa and Miura, 2000), were also
identified. Members of PLP/DM20 family have four transmembrane domains with the N-
and C-terminus localized intracellularly (Figure 1.4A). They show a very high degree of
conservation within their hydrophobic domains, and less conservation in their hydrophilic
regions. PLP is highly conserved through evolution. PLP from mouse, rat and human have
identical amino acid sequence (Milner et al., 1985; Diehl et al., 1986). Similarly, M6a from
mouse, rat and human share over 99% amino acid sequence (Mukobata et al., 2002).
PLP and its spliced isoform DM20 constitute about 50% of the protein in CNS
myelin sheath (Readhead et al., 1994). It is generally believed that PLP/DM20 plays an
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essential structural role in maintaining the multilamellar state required for normal myelin
function by promoting adhesion of bilayers. However the idea that PLP/DM20 is more
than a structural protein for myelination is gaining increasing support (Campagnoni, 1988;
Campagnoni and Skoff, 2001; Greer and Lees, 2002). Although PLP appears to be
expressed by mature oligodendrocytes only, DM20 has been found in oligodendrocytes
well before myelination (Schindler et al., 1990). Moreover, a widespread distribution of
DM20 in diverse non-nervous tissues further supported a PLP/DM20 function unrelated to
myelination (Nadon et al., 1997). Consistent with this view, a role of PLP/DM20 family in
ion transport was previously suggested  (Lin and Lees, 1982; Helynck et al., 1983; Diaz et
al., 1990; Inouye and Kirschner, 1991). Thus, a function of PLP/DM20 family other than
its structural role in myelination is possible. It is tempting to speculate that M6a has a
function similar to that of PLP/DM20 since they share a high sequence homology.
Recently, Mukobata and coworkers (2002) reported that M6a functions as a nerve growth
factor-gated Ca2+ channel and is involved in neuronal differentiation. This is in line with
previous reports that M6a might be involved in vectorial transport and multi-ion transport
(Diaz et al., 1990; Inouye and Kirschner, 1991; Lagenaur et al., 1992; Kitagawa et al.,
1993). Furthermore, previous studies suggested a role for M6 protein (M6a and M6b) in
some aspects of neurite growth. The M6 antigens located on neurites, especially in growth
cones, and the M6 antibody inhibited neurite extension of cultured cerebellar neurons,
presumably resulting from the interference of antibody with a surface antigen of the
neurites by altering intracellular ion concentration (Lagenaur et al., 1992; Yan et al., 1993).
However, according to the observation of M6a localization by immunoelectron
microscopy, Roussel and colleagues (1998) excluded the possibility that the M6a antigen
was responsible for the neuritic inhibition in response to M6 antibody because the M6a
antigen localized at the cytoplasmic side of various membranes. Nevertheless, up to now,
the definitive function of M6a is still unclear.
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1.9 The present research project
The process by which extracellular signals are transferred from cell membrane to
specific intracellular sites is an essential facet for cellular regulation. Various proteins
within plasma membrane and/or by recruitment from cytoplasm greatly affect opioid
receptor trafficking and signaling (Heydorn et al., 2004; Bockaert et al., 2004). Therefore,
identification of opioid receptor-interacting proteins might provide new insights into the
regulatory mechanisms of receptor trafficking and signaling.
Using a yeast two-hybrid system to screen a rat brain cDNA library for proteins that
interact with the µ-opioid receptor, our group identified over fifty proteins interacting with
MOR1 and/or MOR1B. We have employed co-immunoprecipitation to analyze these
interacting proteins. Co-immunoprecipitation relies on in vitro assays that require
solubilization with detergents, which could promote artificial aggregation of hydrophobic
proteins such as transmembraneous proteins. In contrast, BRET (bioluminescence
resonance energy transfer) technology is a living cell-based proximity assay, which
overcomes the drawback of co-immunoprecipitation (Boute et al., 2002; Pfleger and Eidne,
2003; Wang et al., 2005). In BRET assay, the proteins are more likely to be in their native
conformations, which may lead to increased sensitivity and accuracy of detection. Here,
we employ BRET to confirm interactions of MOR1 with those proteins. Of all of those
proteins, M6a shows the strongest interaction with MOR1.
In humans, a variety of mutations of the PLP gene are known to cause the
dysmyelinating disorders Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia
(Hodes and Dlouhy, 1996; Garbern et al., 1999; Inoue, 2005). In mammalian cells,
cholesterol is thought to form membrane microdomains termed lipid rafts that regulate
protein trafficking (Lusa et al., 2001; Golub et al., 2004). PLP directly interacts with
cholesterol in myelin lipid raft (Simons et al., 2000). In normal conditions, internalized
cholesterol is distributed to early and recycling endosomes from where it can recycle back
to the plasma membrane (Mukherjee et al., 1998; Gagescu et al., 2000; Kobayashi et al.,
2001; Lusa et al., 2001). However, over-expression of PLP induces the abnormal
accumulation of PLP and cholesterol in the late endosomal/lysosomal compartment
(Simons et al., 2002). Thus, it is interesting to test whether the interaction between MOR1
and M6a changes the regulation of MOR1 trafficking.
In this thesis, we focus on demonstrating the MOR1-M6a interaction and
characterizing the possible role of M6a in the intracellular trafficking and signal regulation
of the µ-opioid receptor.
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2 Materials
2.1 Instruments
Gene Pulser II and Pulse Controller Plus (Bio-Rad, USA) for Electroporation
dNA sequencer, model 4000   (Li-cor, Germany)
Leica TCS-NT laser-scanning confocal microscope  (Leica Microsystems, Germany)
Fusion™ Universal Microplate Analyzer   (BioSignal Packard BioScience)
PTC-0200 DNA Engine   (MJ Research, Inc. USA) for PCR
TRI-CARB 1900 TR Liquid Scintillation Analyser   (Packard, USA)
Expert Plus Microplate Reader   (ASYS, Austria)
Electrophoresis power supply   (Bio-Rad)
Gel electrophoresis system   (Bio-Rad)
Semi-dry Transfer Cell (Bio-Rad) for electroblotting
2.2 Kits
PCR purification Kit, Gel extraction Kit, Plasmid Midi Kit   (QIAGEN, Germany)
EndoFree Plasmid Maxi Kit   (QIAGEN, Germany)
MinElute Reaction Cleanup Kit   (QIAGEN, Germany)
RNeasy Tissue Kit   (QIAGEN, Germany)
Cyclic AMP (3H) assay system   (Amersham Biosciences, Braunschweig, Germany)
Sequencing kit with 7-deaza-dGTP   (Amersham Pharmacia Biotech)
Micro Bio-Spin columns P-30   (BIO-RAD)
Rat Neuron Nucleofector Kit   (Amaxa Inc. USA)
2.3 Chemicals
DAMGO   (Bachem, Heidelberg, Germany)
[3H]DAMGO   (NEN, Köln, Germany)
Morphine   (Synopharm, Barsbüttel, Germany)
Etorphine   (Gampian Pharamceutical Limited, Dundee Scotland, UK)
Naloxone   (Tocris)
Monensin   (Sigma)
DPDPE   (Bachem, Heidelberg, Germany)
Forskolin   (Biotrend, Köln, Germany)
LipofectamineTM 2000   (Life technologies, Invitrogen)
Dithiobis-(succinimi-dylpropionate)(DSP)   (Pierce)
Enhanced chemiluminescence detection system   (Amersham Biosciences)
DPX mountant for histology (resinous mounting media)  (Fluka, NeuUlm, Germany)
Deep Blue C (coelenterazine)   (BioSignal Packard Biosciences)
Protein A-agarose beads   (Amersham Biosciences, Sweden)
ABTS solution   (Roche Molecular Biochemicals)
Triton-X100   (Merck, Darmstadt, Germany)
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Ammonium persulfate   (Sigma)
30% acrylamide mix   (Carl Roth GmbH & Co)
HEPES, TEMED   (Serva)
2.4 Bacterium and eukaryotic cell line
E. coli XL1   (Promega)
Human embryonic kidney HEK 293 cell   (ATCC CRL 1573)
2.5 cDNAs and plasmids
pCMV-SPORT6-M6a (RZPD, Germany) (GI: 31981997)
pRc/CMV-MOR1 from Dr. Lei Yu (Indianapolis, IN) (GI: 6981309)
pcDNA3.1-MOR1B from Alexander Zimprich (Zimprich et al., 1995)
pCMV-M6b from Prof. Klaus-Armin Nave (Göttingen, Germany) (GI:9502118)
pCMV-DM20 from Prof. Klaus-Armin Nave (Göttingen, Germany) (GI: 200408)
pRK5-mGluR1a and 5a from Dr. Helmut Schröder (IPT,Magdeburg Univ., Germany)
pcDNA3.1-DOR1 from Dr. Manuela Pfeiffer (IPT, Magdeburg Univ., Germany)
pGFP-sst2A from Dr. Stefan Schulz (IPT, Magdeburg Univ., Germany)
pEAK10 expression vector   (Edge Bio Systems, Gaithersburg, MD)
pRluc-N3/C1 and pGFP-N3/C3 vectors   (BioSignal Packard BioScience)
pGEM-T easy vector   (Promega, Madison, USA)
pCMV-HA, pCMV-Myc   (Clontech)
pcDNA3.1   (Invitrogen)
2.6 Mediums
DMEM with 4.5g/L Glucose and L-Glutamine   (Cambrex, Belgium)
OPTIMEM I (Modified Eagle's Minimum Essential Medium)   (Invitrogen)
RPMI medium with Glutamine   (Cambrex, Belgium)
Neurobasal medium   (Gibco)
LB media and LB-Agar media   (Gibco)
Fetal calf serum (FCS)   (Bachem, Heidelberg, Germany)
2.7 Enzymes
All endonucleases from New England Biolab
Taq DNA polymerase, T4 ligase, M-MLV reverse transcriptase from Promega
SP6, T7 polymerase from Roche
RNase A from Sigma
2.8 Antibodies and antibiotics
Mouse anti-Myc monoclonal antibody   (Clontech)
Fluorescent conjugated second antibodies   (Jackson ImmunoResearch, PA)
Rat anti-mouse M6a antibody   (Medical & biological laboratories CO., LTD.)
Peroxidase-conjugated anti-rabbit antibody   (Amersham Biosciences)
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HRP-conjugated second antibodies   (Amersham Biosciences)
Hygromycin B   (PAA Laboratories GmbH, Pasching, Germany)
Puromycin, Ampicillin, Penicillin and Streptomycin   (Sigma)
Zeocin   (Life technologies, Invitrogen)
G418   (Gibco)
2.9 Buffers and solvents
Zamboni’s fixative:
4% paraformaldehyde and 0.2% picric acid in phosphate buffer, pH 6.9.
Immunoprecipitation buffer:
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM
disodium pyrophosphate, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, and the following proteinase inhibitors: 0.2 mM phenylmethyl-
sulfonyl fluoride, 10 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin,
and 10 µg/ml bacitracin. (Proteinase inhibitors were added prior to use)
SDS-sample buffer:
62.5 mM Tris-HCl, pH 6.8, 2% SDS, 20% glycerol, 0.005% bromphenol
blue, 100 mM DL-dithiotreitol. (Dithiotreitol was added prior to use)
1 x TPBS (Tris/phosphate-buffered saline):
10 mM Tris, 10 mM phosphate buffer, 137 mM NaCl and 0.05% thimerosal,
pH 7.4.
In situ hybridization buffer:
600 mM NaCl, 10 mM TrisCl pH 7.5, 1 mM di-Na-EDTA, 0.05% (w/v)
tRNA, 1 x Denhardt’s solution, 50% dextransulfate, 100 µg/ml sonicated
salmon sperm DNA, 50% formamide, 20 mM DTT.
Buffer 1:
100 mM maleic acid, 150 mM NaCl, pH 7.5
Buffer 2:
100 mM Tris, 100 mM NaCl, 50 mM MgCl2, pH 9.4, 0.05% Triton-X100.
RNase-buffer:
10 mM TrisCl, pH 8.0, 0.5 M NaCl, 1 mM EDTA, 40 µg/ml RNase A, 1
unit/ml RNase T1.
SSC (sodium chloride/sodium citrate), 20x:
3.0 M NaCl, 0.3 M Na3citrate.2H2O, PH7.0
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3 Methods
3.1 Gene subclone
In the following experiments, the related PCR, ligation, transformation by calcium
chloride or electroporation, plasmid preparation, purification and identification were
carried out using a standard molecular clone protocol or according to manufacturer’s
instruction.
3.2 Plasmid sequencing
To confirm the plasmid constructions, all subclones were sequenced using the
Thermo Sequenase fluorescent labelled primer cycle sequencing kit according to the
manufacturer’s protocol.
3.3 Co-immunoprecipitation
The pCMV-Myc-M6a plasmid was constructed by the subcloning of M6a gene
(pCMV-SPORT6-M6a) into pCMV-Myc expression vector by PCR. In 100-mm dish,
HEK293 cells stably expressing HA-MOR1 (in method 3.7) were transiently transfected
with pCMV-Myc-M6a plasmid using Lipofectamine 2000 according to the manufacturer’s
protocol. 48 h after transfection, cells were incubated in OPTIMEM I medium for at least
30 min before incubating with 6 ml cross-linking buffer (PBS containing 10 mM Hepes
(pH 7.4) and 2 mM DSP) for 20-30 min at room temperature. Subsequently, cells were
lysed in 1 ml of ice-cold immunoprecipitation buffer at 4°C for 45 min with gentle
shaking. After centrifugation at 40,000 x g for 1 h, the supernatant was collected. The
receptor proteins were then immunoprecipitated with 100 ml of protein A agarose beads
preloaded with 10 mg anti-HA antibodies at 4oC for over night. Beads were washed five
times with the immunoprecipitation buffer, and immunoprecipitates were eluted from the
beads with 100 ml of SDS-sample buffer at 60°C for 20 min. The receptor or M6a protein
was separated with regular 8% or 12% SDS-polyacrylamide gel electrophoresis. After
electrophoresis, proteins were transferred from the gel to nitrocellulose membrane by
electroblotting. Then membranes were incubated with either mouse monoclonal anti-Myc
or affinity-purified rabbit anti-HA antibody at a concentration of 1 mg/ml for over night at
4°C. Immunoreactive bands were visualized by detection using an enhanced
chemiluminescence detection system.
3.4 BRET assay
3.4.1 Principle
Bioluminescence resonance energy transfer (BRET) technology is a proximity assay
based on non-radiative transfer of energy between a bioluminescent donor (Renilla
luciferase, Rluc) and a fluorescent acceptor (Green Fluorescent Protein, GFP) that allows
real time monitoring of protein-protein interaction in living cells. In our experiments, an
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advanced BRET (also termed BRET2, BioSignal Packard BioScience) was used. For
BRET principle, see Figure 3.1.
Figure 3.1. BRET principle. Resonance Energy Transfer occurs when part of the energy from
DeepBlueC (DBC)-bound Rluc is transferred to GFP, which in turn, emits green light. If Rluc and GFP
are not in close proximity (upper left panel), energy is not efficiently transferred and only the blue light
emitted by the Rluc/DBC reaction is detected. When Rluc and GFP are brought into close proximity
(lower left panel), by means of a specific biological interaction between protein A and protein B (fused
to Rluc and GFP, respectively), energy is efficiently transferred from DBC-bound Rluc to GFP resulting
in the production of green light. The BRET signal is determined by measuring the ratio of green light
(515nm) over blue light (410nm) (right panel).
3.4.2 Donor and acceptor plasmid construction and co-transfection
The coding sequences without a stop codon of MOR1 and its truncations, or
MOR1B, DOR1, sst2A, mGluR1a and mGluR5a were amplified by PCR, and then were
ligated into humanized pRluc-N3 expression vectors to produce BRET donors. The coding
sequences of M6a and its truncation, or M6b and DM20 were amplified by PCR, and then
were subcloned into humanized pGFP-C3 expression vectors to produce BRET acceptors.
The day prior to transfection, HEK293 cells were seeded in a 24-well plate. Cells
were 90-95% confluent before transfection. Cells were co-transfected with donor and
acceptor plasmids using Lipofectamine 2000 according to the manufacturer’s protocol.
3.4.3 BRET detection
45 h post-transfection, cells were detached with PBS/0.5mM EDTA and resuspended
in PBS containing 0.1% glucose and 2µg/ml aprotinin. Cells were then transferred to 96-
well microplates at a density of about 1 x 105 cells/well. Deep Blue C was added at a final
concentration of 5 µM, and readings were collected immediately using the Fusion™
Universal Microplate Analyzer that allows the sequential integration of the signals detected
in the 330-490 nm and 485-545 nm windows using filters with the appropriate band pass.
The following settings were used: Mode: dual wavelength; Read length: 1 second per
wavelength; PMT: 1100 volts; Gain: 100; Filter pair: 410/80 nm (Rluc emission) and
515/30 nm (GFP emission). The values were corrected by subtracting background signal
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detected in untransfected cells. The BRET signal was determined by calculating the ratio
of the light emitted by the GFP over the light emitted by the Rluc as shown in the
following formula.
 (emission at 515 nm)-(background emission at 515 nm)
BRET signal =
 (emission at 410 nm)-(background emission at 410 nm)
3.5 Immunocytochemistry
Cells were grown on poly-L-lysine-treated coverslips for overnight. After treatment
as indicated in text or without treatment, cells were fixed with Zamboni’s fixative for 40
min at RT. Then cells were washed several times with TPBS. Specimens were then
incubated for 3 min in 50% and 100% methanol respectively to permeabilize membrane.
Subsequently specimens were washed several times in TPBS and then preincubated with
TPBS containing 3% normal goat serum for 2 h at room temperature. Then cells were
incubated with mouse anti-Myc antibody and/or rabbit anti-HA antibody at a concentration
of 0.5 mg/ml in TPBS containing 1% normal goat serum overnight. Bound primary
antibodies were detected with relative cyanine 2.18 (Cy2)- and/or 3.18 (Cy3)-conjugated
second antibodies (1:400 or 3.75 mg/ml). Cells were then permanently mounted in DPX.
Specimens were examined using a Leica TCS-NT laser-scanning confocal microscope,
equipped with a krypton/argon laser. Cyanine 2.18 was imaged with 488 nm excitation and
530 nm emission filters, and cyanine 3.18 was imaged with 568 nm excitation and 570-630
nm band pass emission filters.
To observe the trafficking of surface MOR1 and/or M6a, cells were firstly surface-
labeled with rabbit anti-HA and/or rat anti-M6a antibody at a final concentration of 1.0
µg/ml at 4°C for 1.5 h. Cells were subsequently treated as shown in text, and then fixed
normally. The bound primary antibodies were detected as described above.
3.6 In situ hybridization
3.6.1 Brain section preparation
Male Wistar rats aged 8 weeks (Dimed, Schonwalde, Germany) were housed under
controlled laboratory conditions (12 h light/dark cycle, temperature 20 ± 2°C, humidity
50–60%). For all procedures, ethical approval was obtained according to the requirements
of the German National Act on the Use of Experimental Animals.
Animals were killed by chloral hydrate (1 g/kg body weight, i.p.). The removed
brains were frozen in isopentane at –30°C to –40°C and cut in a cryostat (15 µm). Sections
were mounted on adhesive slides (Superfrost), and stored at –70°C. Before hybridization,
frozen slides were air-dried, fixed in 4% paraformaldehyde dissolved in phosphate-
buffered saline (PBS) at 4°C for 1 h. After washing in PBS, the slides were treated for 10
min with 0.4% Triton-X 100 in PBS. Next, slides were rinsed in distilled water, and then
treated for 10 min with 1.5% tri-ethanolamine/PBS, containing 0.25% acetic anhydride
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(Sigma). Finally, slides were washed in distilled water and dehydrated in 50% and 70%
iso-propanol, air dried, and stored at -20°C.
3.6.2 Synthesis of RNA probes for in situ hybridization
The previously characterized probe of rat MOR1 (Stumm et al., 2004) was kindly
provided by Dr. Ralf Stumm. To generate the probes of M6a, M6b and DM20, their coding
sequences were amplified by PCR, and then subcloned into the pGEM-T easy vector. For
in-vitro-transcription, the plasmids were linearized with restriction endonucleases and
purified using the MinElute Reaction Cleanup Kit. Synthesis of [35S]-labelled probes was
done in the presence of 100-150 pmol [35S]-labeled UTP in a total reaction volume of 10
µl. The reaction mix further contained 1 µg linearized plasmid-DNA, 10 mM dithiothreitol
(DTT), 0.5 mM unlabeled nucleotides (without UTP). For digoxigenin-labeled probes, a 1
mM nucleotide mixture containing 0.35 mM digoxigenin-11-UTP (Roche, Mannheim) was
used. The transcription was performed with SP6 or T7 polymerase. To improve
permeability, the probes were subjected to partial alkaline hydrolysis, which produces short
probes (final size: 200-300 nucleotides). The labeled probes were finally purified with
Micro Bio-Spin columns P-30.
3.6.3 Hybridization and washing
Radioactive probes were diluted at 50,000 dpm/µl in in situ hybridization buffer. To
each dried slide containing two sections, 45-µl hybridization mixture was added.
Hybridization was performed overnight at 60°C in a humid chamber containing 50%
formamide. Post-hybridization procedures consisted of a sequence of washes with
decreasing salt concentration. Briefly, the slides were washed in 2 x SSC and 1 x SSC
before a 30 min treatment in RNase-buffer at 37°C. Then the slides were extensively
washed in 1 x and 0.2 x SSC at room temperature and subsequently in 0.2 x SSC for 60
min at 60°C. After washing in water, the tissue was dehydrated in 50% and 70%
isopropanol.
3.6.4 Detection of signals
A sheet of x-ray film (b-max, Amersham) was laid over the sections and exposed for
1 to 3 days. For high-power bright- and dark-field microscopic analyses, autoradiographic
detection of 35S was performed by coating the slides with 50% NTB-2 nuclear emulsion
(Eastman Kodak, Rochester, NY). Exposure time for autoradiography varied between 1
and 3 weeks. After emulsion coating, sections were stained with 0.5% cresyl violet (Fluka,
NeuUlm) in 60 mM sodium acetate and 340 mM acetic acid. In each experiment, the
comparison of slides hybridized with sense and antisense probes allowed to decide if a
particular signal was due to specific hybridization or was background.
3.6.5 Double in situ hybridization histochemistry
The visualization of two different mRNA transcripts in the same tissue section was
performed by combining radioactive and nonradioactive in situ hybridization as described
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(Stumm et al., 2002). Digoxigenin-labeled riboprobes were diluted in radioactive
hybridization solution to 1 µg/ml, hybridized, and washed as above. To detect
nonradioactive hybrids, slides were equilibrated in buffer 1 containing 0.05% Triton-X100.
After blocking for 1 h in blocking buffer (buffer 1 containing 2% blocking reagent (Roche)
and 0.05% Triton-X100), alkaline phosphatase conjugated anti-DIG Fab fragments
(Roche) were applied overnight at a concentration of 0.5 unit/ml blocking buffer. Next,
slides were washed twice for 15 min in buffer 1 and equilibrated in buffer 2 prior to a
chromogenic reaction using 0.2 mM 5-bromo-4-chloro-3-indolyl phosphate and 0.2 mM
nitroblue tetrazolium salt (Roche). The reactions (5h for DM20, 22h for M6a and M6b)
were stopped by washing the slides in distilled water. The slides were then dehydrated, and
the 35S-labeled probes were detected by 50% K5 photo-emulsion (Ilford).
3.7 Cell culture and generation of stable cell lines
HEK293 cells were maintained in DMEM supplemented with 10% FCS in a
humidified incubator with an atmosphere containing 10% CO2, at 37°C.
MOR1 and DOR1 were tagged at their NH2 terminus with HA epitope tag using
PCR and then subcloned into pEAK10 expression vector. M6a was tagged at its NH2
terminus with Myc epitope tag using PCR and then subcloned into pcDAN3.1 expression
vector. According to manufacturer’s protocol, HEK293 cells were first transfected with
pEAK10-HA-MOR1, pEAK10-HA-DOR1 or pcDAN3.1-Myc-M6a plasmid using the
Lipofectamine 2000. Stable transfectants were selected in the presence of 1.25 µg/ml
puromycin or 400 µg/ml hygromycin B. To generate the cell line co-expressing HA-MOR1
and Myc-M6a, cells stably expressing HA-MOR1 were subjected to a second round of
transfection with pcDAN3.1-Myc-M6a plasmid as above, and stable transfectants were
selected in the presence of 1.25 µg/ml puromycin and 400 µg/ml hygromycin B. Stably
transfected multi-clones in similar receptor density identified by radioligand binding assay
and ELISA quantitative assay were used for further studies. Receptor and/or M6a
expression were monitored using radioligand binding assay, western blot analysis, and/or
confocal microscopy.
3.8 Calcium-phosphate-mediated transfection of HEK293 cells
24 h before transfection, harvest exponentially growing cells by trypsinization and
replate them at a density of about 2 x 105 cells per well in 12-well plates in 1ml complete
growth medium (DMEM with 10% FCS). Incubate the cultures for 20-24 h at 37°C in a
humidified incubator with an atmosphere containing of 10% CO2. Change medium 1 h
before transfection. For a transfection in one well of 12-well plate, prepare the calcium
phosphate-DNA coprecipitate as follows: Combine suitable H2O, 1.4 µg of plasmid DNA
and 5 µl of 2.5 M CaCl2 to a final volume of 50 µl. Mix 1 volume of this 2 x calcium-DNA
solution with an equal volume of 2 x HEPES-buffered saline (280 mM NaCl, 50 mM
HEPES, 1.5 mM Na2HPO4, pH 7.05). Quickly mix the ingredients and allow the solution
to stand for 20 min at RT. Immediately transfer the calcium phosphate-DNA suspension
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into the medium above the cell monolayer. Rock the plate gently to mix the medium, and
incubate them for 16-18 h at 35°C in a humidified incubator with an atmosphere
containing of 3% CO2. Change the medium with complete growth medium and return the
cells to the incubator (10% CO2, 37°C) for 1-2 days.
3.9 Radioligand binding assay
The binding characteristics of the µ-opioid receptor were determined by saturation
binding assays on membranes prepared from stably transfected HEK293 cells expressing
HA-MOR1 with and without Myc-M6a. Dissociation constant (KD) and number of
[3H]DAMGO binding sites (Bmax) were calculated by Scatchard analysis using at least
seven concentrations of radioligand in a range from 0.25 to 10 nM as previously described
(Koch et al., 2003). Nonspecific binding was determined as radioactivity bound in the
presence of 1 µM unlabeled DAMGO.
Radioligand binding assay is sensitive to calculate the receptor amount. The number
of [3H]DAMGO binding sites in membrane binding assay reflects the amount of total µ-
opioid receptor, which can be used to evaluate the receptor down-regulation.
3.10 Quantitative analysis of receptor internalization and recycling by ELISA
To estimate receptor internalization, cells were seeded at a density of 5.0 x 104 per
well and grown onto poly-L-lysine-treated 96-well plate overnight. Surface HA-MOR1
receptors were specifically labeled with anti-HA antibody (1 µg/ml) in OPTIMEM I at 4°C
for 1.5 h. Cells were then incubated with or without 1 µM DAMGO at 37°C for 30 min.
Subsequently, cells were fixed and incubated with peroxidase-conjugated anti rabbit
antibody (1:1000) for 2 h at RT. Plates were developed with 50 µl ABTS solution per well.
Colour reaction was analyzed at 405 nm using an Expert Plus Microplate Reader during
15-25 min in real time. Endocytosed receptors were evaluated as the loss of surface-labeled
receptors. To measure receptor recycling, cells were first exposed to 10 µM etorphine for 2
h to drive agonist-induced receptor internalization to a steady-state level, then rinsed with
OPTIMEM I, and subsequently incubated at 37°C for 30 and 60 min in the presence of 10
µM naloxone to block residual agonist-stimulated receptor internalization. Cells were then
chilled with 4°C PBS to stop trafficking, and receptors were surface-labeled with anti HA
antibody (1µg/ ml) at 4°C for 2h. Un-binding antibodies were washed out, cells were fixed
and surface receptors were detected as described above. Recycling rate was estimated as a
percent of recovered surface receptors to endocytosed receptors.
3.11 Cloning of M6a cDNA by RT-PCR
Total RNA of HEK293 cells was extracted according to manufacturer’s instruction.
Reverse transcription: Reverse transcription mix consisted of 1µg total RNA, 0.5µM
oligo(dT)15, 0.5mM dNTPs, 100 units of reverse transcriptase and 2µl of 5x reaction
buffer in a total 10 µl reaction volume. Simply, total RNA (1µg in 5µl) was firstly
denatured at 65°C for 10 min, cooled on ice and then mixed with the other reaction
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solution (5µl). The reaction mixture (10µl) was incubated at 42°C for 1 h, followed by
75°C for 15 min, and then frozen at -20°C. For contamination controls, water was used
instead of total RNA. The total cDNA was used as template to amplify M6a coding
sequence by standard PCR using the following primers. Forward primer 5´-GAA GAA
GAA TTC CC ATG GAA GAG AAT ATG G-3´ introduced EcoR I restriction site, and
reverse primer 5´-AGA GAA GGT ACC TTA TGT GTA CGC ATT GAG-3´ introduced
Kpn I restriction site. PCR products were subsequently subcloned into humanized pGFP-
C3 vector for both sequencing and BRET assay.
3.12 Transferrin trafficking
A previously described “pulse-chase” assay (Tsao and von Zastrow, 2000; Tulipano
et al., 2004) was used to estimate the degree to which a “pulse” of internalized opioid
receptor and M6a was accessible to a subsequent “chase” of endocytosed transferrin.
Stable HA-DOR1 cells transiently transfected with pCMV-Myc-M6a plasmid using
calcium phosphate precipitation method, and cells stably co-expressing HA-MOR1 and
Myc-M6a were used. Cells were grown on poly-L-lysine coated coverslip. Receptor and
M6a were surface-labeled with rabbit anti-HA and rat anti-M6a antibody (1 µg/ml) at 4°C
for 1.5 h. In the first set of experiments, cells were simultaneously incubated with 10 µM
DAMGO (or DPDPE) and 5 µg/ml Alexa Fluor 488-conjugated transferrin (Molecular
Probes) for 30 min at 37°C. In a second set of experiments, cells were first incubated with
10 µM DAMGO (or DPDPE) for 30 min at 37°C to drive the internalization of antibody-
labeled receptor and M6a, then rinsed three times with calcium, magnesium-free PBS with
1.6% EDTA. Subsequently, cells were rewarmed at 37°C for 20 min in agonist-free media
containing 5 µg/ml Alexa Fluor 488-conjugated transferrin, conditions which label both
early and recycling endosomes (Dunn et al., 1989). Cells were then fixed, permeabilized.
Subsequently, antibody-labeled receptor and M6a were detected using a mixture of cyanine
5.18-conjugated anti-rabbit and cyanine 3.18-conjugated anti-rat second antibodies. Alexa
Fluor 488 was imaged with 488 nm excitation and 530 nm emission filters, cyanine 3.18
was imaged with 568 nm excitation and 570-630 nm bandpass emission filters, and
cyanine 5.18 was imaged with 647 nm excitation and 665 nm long pass emission filters.
3.13 Primary neuronal cell culture, transfection and immunostaining
Neuronal cultures were prepared from rat cortex of embryonic day 17 embryos
(E17). All animal procedures were approved by Otto-von-Guericke-University Magdeburg.
Using 12-well plate with poly-D-lysine-coated coverslips, seed primary cortical cells at 4 x
105 cells/well in 1.5 ml Neurobasal medium supplemented with 2% B-27, 0.5 mM
Glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Cells were cultured at
37°C and 5% CO2 in a humidified incubator. Remove 1/2 volume of the medium on day 3
after seeding and replace with fresh medium.
The cording region of MOR1 was amplified using PCR, and then subcloned into
pCMV-HA expression vector, which generates amino-terminally HA-tagged MOR1. The
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cording region of M6a was amplified using PCR, and then subcloned into pcDNA3.1
expression vector. These constructs and the construct of amino-terminally Myc-tagged
M6a (pCMV-Myc-M6a) described in method 3.3 were used for transient transfection.
Primary neuronal cultures on day 4 were transfected with MOR1 and/or M6a
plasmid using Lipofectamine 2000 following the manufacturer’s instruction. 40 hours after
transfection, cells were treated and subsequently fixed with Zamboni’s fixative. To observe
the trafficking of surface receptor and M6a, cells were surface-labeled by specific anti-HA
antibody and/or anti-M6a antibody (2 µg/ml) at 4°C for 1 hour. Subsequently cells were
treated or not treated as shown in text, and then fixed. Distribution of expressed interesting
proteins was detected by immunocytochemistry as described above.
3.14 Determination of receptor desensitization
2.5 x 105 cells per well were seeded in poly-L-lysine-coated 24-well plate overnight.
Cells were then exposed to agonist or agonist plus 50 µM monensin for different period.
For the measurement of cAMP accumulation, cells were first washed one time with 0.5 ml
serum-free RPMI medium. Immediately, medium was removed and replaced by 0.25 ml
serum-free RPMI medium containing 25 µM forskolin with or without agonist. The cells
were incubated at 37°C for 15 min. After one time wash with cold PBS, the intracellular
cAMP was extracted immediately with 0.5 ml of cold HCl/ethanol (1 volume of 1 N
HCl/100 volumes of ethanol, stored at -20°C). The supernatant was transferred into a 1.5
ml tube, and then evaporated by vacuum at 30°C. The residue of cAMP was frozen at -
20°C or for further examination. The extracted cAMP content was determined using a
commercially available cyclic AMP (3H) assay system.
For the determination of receptor desensitization in primary neuronal cells, fresh
prepared cortical cells (E17) were transfected with MOR1 and/or M6a plasmid using Rat
Neuron Nucleofector Solution according to the manufacturer’s protocol. After transfection,
6.0 x 105 cells per well were seeded into poly-D-lysine-coated 24-well plate, and grew in
DMEM medium supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml
streptomycin. After overnight, carefully replace the medium with Neurobasal media
supplemented with 2% B-27, 0.5 mM Glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin. 4-5 days after transfection, cells were then exposed to 10 µM DAMGO for
0, 1 and 4 h. Cells were then washed one time with 0.5 ml serum-free DMEM medium.
Subsequently, medium was removed and replaced by 0.25 ml serum-free DMEM medium
containing 5 µM forskolin in the presence or absence of 10 µM DAMGO. The cells were
incubated at 37°C for 10 min. The cAMP accumulation was determined as described
above.
3.15 Data analysis
Statistic significant difference was analyzed by one-way ANOVA followed by
bonferroni test using GraphPad Prism 4.0 software. All graphs in the following were
drawed by the same software.
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4 Results
4.1 Co-immunoprecipitation of MOR1 and M6a
To confirm whether the strong interaction of MOR1 with M6a in yeast also occurs in
mammalian cells, we carried out co-immunoprecipitation experiments in HEK293 cell co-
transfected with epitope tagged MOR1 and M6a. MOR1 was labeled with the HA epitope
(HA-MOR1), and M6a with the Myc epitope (Myc-M6a) both at the amino terminus.
Figure 4.1. Co-immunoprecipitation of HA-MOR1 with Myc-M6a. Cell lysate proteins from cells
co-expressing HA-MOR1 and Myc-M6a were extracted and either immunoblotted directly (lane 1,
lysate) or immunoprecipitated using anti-HA antibodies (lane 2, IP HA). Cell lysate proteins from cells
expressing HA-MOR1 alone were extracted and immunoprecipitated using anti-HA antibodies (lane 3,
IP HA). Lysate proteins from cells transiently over-expressing Myc-M6a alone were extracted and
either immunoblotted directly (lane 5, lysate) or immunoprecipitated using anti-HA antibodies (lane 4,
IP HA). The resulting immunoprecipitates were electrophoretically separated, transferred to
nitrocellulose membrane and detected with anti-Myc or anti-HA antibodies. The mobility of molecular
mass standards (in kDa) is indicated to the left. Arrows point to M6a or MOR1. Two additional
experiments gave similar results.
As shown in Figure 4.1, expression of HA-MOR1 and Myc-M6a was examined by
directly immunoblotting lysates from these cells with specific antibodies against HA and
Myc tag, respectively (lane 1 and 5, lysate). For co-immunoprecipitation, receptors were
precipitated from the lysates of cells expressing HA-MOR1 with and without Myc-M6a
using anti-HA antibodies. The resulting precipitates were immunoblotted with antibodies
directed against Myc epitope tag. As shown in Figure 4.1 (lane 2, IP HA), Myc-M6a
migrating at about 30 kDa was detected in immunoprecipitates from cells co-expressing
HA-MOR1 and Myc-M6a, suggesting that MOR1 is physically associated with M6a in
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vivo. In immunoprecipitates from HA-MOR1 or Myc-M6a expressing control cells, no
Myc-M6a was detected (Figure 4.1, lane 3 and 4, IP HA, respectively), indicating the
specific interaction between MOR1 and M6a.
4.2 Analysis of protein-protein interaction by BRET
Detergent solubilization of cells during co-immunoprecipitation studies could
promote artificial aggregation of hydrophobic proteins such as transmembraneous proteins.
We therefore analyzed protein-protein interaction in living HEK293 cells using a
biophysical method, BRET. This technique is a proximity assay based on non-radiative
transfer of energy between a bioluminescent donor (Rluc) and a fluorescent acceptor (GFP)
that allows real time monitoring of protein-protein interaction in living cells. M6a is a
member of the proteolipid protein (PLP)/DM20 family, and shows high homology with
M6b and DM20 (Yan et al., 1993). We therefore investigate whether MOR1 also interacts
with M6b and DM20.
Figure 4.2. The interaction of MOR1 with members of PLP/DM20 family. HEK293 cells were
transiently cotransfected with MOR1-Rluc in the combination with GFP (negative control), GFP-M6a,
GFP-M6b or GFP-DM20. A treatment of GFP-Rluc fusion protein was used as positive control. Cells
were harvested 45 h post-transfection, and were incubated in the BRET buffer for 30 min. The energy
transfer was initiated by addition of 5 µM Deep Blue C, and BRET signal was assessed in a Fusion™
Universal Microplate Analyzer as described under “Methods”. The results represent mean ± SEM of 3-5
independent experiments performed in duplicate. Asterisk indicates an extremely significant difference
(P<0.001, compared with negative control) analyzed by one-way ANOVA followed by Bonferroni test.
In the BRET assay, the fusion construct linking Rluc to the MOR1 carboxyl terminus
was co-transfected in combination with the fusion construct linking GFP to the amino
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terminus of M6a, M6b or DM20 in HEK293 cells. 45 hours after transient co-transfection,
the transfer of energy between the two partners was assessed following the addition of
Deep Blue C. In the presence of oxygen, Rluc catalyzes the transformation of Deep Blue C
into coelenteramide with concomitant light emission peaking at 395 nm (blue light) that
can excite GFP, which in turn, re-emits fluorescence with a peak at 510 nm but only when
the two partners are within the BRET-permissive distance (<10nm). The BRET signal is
determined by calculating the ratio of the light emitted by the GFP fusion protein over the
light emitted by the Rluc fusion protein.
As shown in Figure 4.2, a high BRET signal was obtained with the GFP-Rluc fusion
protein in positive control (Positive), whereas a very low BRET signal was obtained when
MOR1-Rluc was co-expressed with GFP in negative control (Negative). A significantly
high BRET signal was obtained in cells co-expressing MOR1-Rluc with GFP-M6a or
GFP-M6b, but not with GFP-DM20. This finding indicated that a specific constitutive
interaction of MOR1 with M6a or M6b occurs in living cells.
4.3 Agonist-mediated subcellular distribution of MOR1-M6a/M6b
In baby-hamster kidney-cell line (BHK cells), cultured oligodendrocytes and
transgenic mice, previous research showed that over-expression of the proteolipid protein
(PLP) induces the abnormal accumulation of PLP, cholesterol, and other lipid raft
components in the late endosomal/lysosomal compartment (Simons et al., 2002). Since
M6a and M6b show high homology with PLP (Yan et al., 1993), it is interesting to analyze
whether over-expression of M6a or M6b influences agonist-mediated subcellular
distribution of the µ-opioid receptor (MOR1).
In HEK293 cells stably co-expressing HA-MOR1 and Myc-M6a, M6a was localized
both at the plasma membrane and in the cytoplasm. MOR1 was predominantly distributed
at the plasma membrane, and was shown to co-localize with M6a both at the plasma
membrane and in the cytoplasm (Figure 4.3A, control). In MOR1-M6b co-expressing cells,
M6b was mainly localized at the plasma membrane, and was shown to co-localize with
MOR1 (Figure 4.3B, control).
After treatment of MOR1 with agonist together with the recycling blocker monensin,
MOR1 and M6a were detected mainly in cytoplasm and showed strict co-localization
(Figure 4.3A, lower panel). In remarkable contrast, there was no distinct change in M6b
subcellular distribution and no major co-localization between MOR1 and M6b after MOR1
internalization (Figure 4.3B, lower panel) though the interaction between MOR1 and M6b
was stronger than that of MOR1 and M6a (Figure 4.2).
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Figure 4.3. Agonist-mediated subcellular distribution of HA-MOR1 with Myc-M6a/M6b. HEK293
cells stably expressing HA-MOR1 were transiently transfected with Myc-M6b plasmid. Three days
after transfection, cells were exposed to 1 µM DAMGO and 50 µM monensin for 2 hours at 37°C.
Simultaneously, cells stably co-expressing HA-MOR1 and Myc-M6a were treated in the same way.
Cells were subsequently fixed, and the receptor and M6a/M6b were visualized by confocal microscopy
as described under “Methods”. Representative images from two independent experiments are shown.
Scale bar, 16 µm.
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This finding that MOR1 and M6a co-localized and co-internalized in the presence of
µ-opioid receptor agonist suggested that M6a might function as a scaffold, anchoring or
adaptor protein in receptor trafficking. The absence of co-internalization of MOR1 and
M6b implied that M6b might be involved in other steps of MOR1 regulation. Since our
interest is the intracellular trafficking of the µ-opioid receptor, we first focus on the
analysis of the possible role of M6a in MOR1 regulation.
4.4 Analysis of MOR1-M6a interacting domains by BRET
To estimate the binding domains of MOR1 and M6a, a series of truncation mutants
of MOR1 and M6a were generated by PCR mutagenesis. The interactions between these
truncations and full length of MOR1 or M6a were analyzed by BRET assay.
As depicted in Figure 4.4B, the carboxyl terminal tails (340-398aa) of MOR1 failed
to interact with the full length of M6a, whereas the MOR1 truncation (1-339aa), like full
length MOR1 (1-398aa), interacted strongly with the full length of M6a. This demonstrated
that MOR1 carboxyl terminal tail, which plays a key role in the regulation of MOR1
signaling, is not the direct interacting domain for MOR1-M6a interaction. For the
interaction between MOR1 truncations (1-124aa, 105-258aa or 258-339aa) and the full
length of M6a, there was no significant BRET signal. Furthermore, we found that the
truncation (186-303aa) of MOR1 plays an important role in MOR1-M6a interaction
because only this short truncation can interact with the full length of M6a.
As shown in Figure 4.4C, according to BRET signals, the M6a truncation (108-
278aa) interacted strongly with the full length of MOR1. When the M6a mutant (108-
278aa) was truncated into two parts (108-163aa and 164-278aa), both fragments failed to
interact with the full length of MOR1, suggesting that the second extracellular large loop of
M6a plays a major role in MOR1-M6a interaction. However, the 2nd extracellular loop
(152-225aa) itself showed no interaction with the full length of MOR1 (Figure 4.4C),
indicating that the 3rd and 4th transmembrane domains together with the 2nd extracellular
loop, are necessary to form a MOR1 binding domain. This is in agreement with the finding
that there is an interaction between the M6a truncation (129-255aa, the 3rd and 4th
transmembrane domains plus the 2nd extracellular loop) and the full length of MOR1. In
addition, there was also an interaction between the amino terminal truncation (1-108aa) of
M6a and the full length of MOR1. This finding suggested that M6a has two binding
domains, and the region of 129-255aa is the predominant binding sequence. Taken
together, the transmembrane domains of MOR1 and M6a are important for their
interaction.
4. Results                                                                                                                                        -28-
A.
B.  MOR1
 
C.    M6a
4. Results                                                                                                                                        -29-
Figure 4.4. Analysis of specific binding domains between MOR1 and M6a. A. Schematic structure
of MOR1 and M6a, the number in the structure pattern represents the position of relative amino acid
(black dot). B.  Full length M6a interacted with different truncation mutants of MOR1. Cells were
transiently cotransfected with GFP-M6a in combination with Rluc-tagged full length MOR1 (1-398aa)
or its truncation mutants. MOR1-Rluc in combination with GFP was set as the negative control. Cells
were harvested 45 h post-transfection. The energy transfer was detected as described under “Methods”.
C. The full length of MOR1 interacted with different truncation mutants of M6a. Cells were transiently
cotransfected with MOR1-Rluc in combination with GFP (negative control), GFP-tagged full length of
M6a (1-278aa) or its truncation mutants. The protein-protein interaction was detected as described
above. The results represent mean ± SEM of 3-5 independent experiments performed in duplicate.
Asterisk indicates an extremely significant difference (P<0.001, compared with negative control)
analyzed by one-way ANOVA followed by Bonferroni test.
4.5 BRET-analysis of M6a interaction with various GPCRs
Next we asked, is it possible that M6a interacts with other GPCRs because of their
high homology at transmembrane domains?
Figure 4.5. Analysis of M6a interaction with GPCRs. Cells were transiently cotransfected with GFP-
M6a in combination with Rluc tagged GPCRs. MOR1-Rluc in combination with GFP was set as the
negative control. Cells were harvested 45 h post-transfection. The energy transfer was detected as
described under “Methods”. Note that M6a interacts with µ- and d-opioid receptors, the somatostatin
receptor 2A (sst2A), but not with the metabotropic glutamate receptors (mGluR1a, 5a). Negative
controls in the combination of different Rluc tagged receptors with GFP were used, and there was no
significant difference between these negative controls. The results represent mean ± SEM of 3-5
independent experiments performed in duplicate. Asterisk indicates an extremely significant difference
(P<0.001) analyzed by one-way ANOVA followed by Bonferroni test.
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As shown in Figure 4.5, M6a interacted strongly with both µ-opioid receptor
isoforms MOR1 and MOR1B. The stronger interaction of M6a with MOR1B as compared
to MOR1, indicated that the carboxyl tail might influence the interaction though the
carboxyl tail of MOR1 was not the direct interacting domain (Figure 4.4B). M6a interacted
also with the d-opioid receptor (DOR1)(Figure 4.5). In addition, M6a also interacted with
the somatostatin receptor 2A (sst2A), suggesting that M6a interacts not only with opioid
receptors, but also with other GPCRs. However, this does not mean that M6a is an
associated protein for all GPCRs. For instance, we have not detected an interaction
between M6a and metabotropic glutamate receptors (mGluR1a and 5a). This finding
suggested that M6a might play a role in the regulation of certain GPCRs.
4.6 Formation of a dimer (oligomer) of MOR1 or M6a
Receptor dimerization/oligomerization is a potential mechanism for the modulation
of receptor function, and involved in cell surface targeting, internalization and signaling of
receptors (Salahpour et al., 2000). Dimerization/oligomerization of opioid receptors has
been suggested to play a role in receptor activation and internalization (Cvejic and Devi,
1997; Jordan and Devi, 1999; George et al., 2002; He et al., 2002; Gomes et al., 2004;
Waldhoer et al., 2005). The µ-opioid receptor has been shown to form the homo- and
hetero-dimers in different transfected cell lines using biochemical assays (Koch et al.,
2001; Gomes et al., 2000). In the present study, we investigated whether the formation of
dimers (oligomers) of MOR1 can also be detected by BRET, a biophysical method. As
shown in Figure 4.6A, the formation of a dimer (oligomer) of MOR1 was detected by
BRET. Interestingly, the significant BRET signal of MOR1 dimerization occurred only in
the combination of carboxyl-terminally Rluc- and GFP- tagged MOR1. This finding
indicated that the formation of dimers occurs by the binding of MOR1carboxyl-parts.
A previous study has demonstrated that PLP and DM20 form stable dimers, which
are involved in the transportation of PLP to the plasma membrane in HeLa cells (Sinoway
et al., 1994). We therefore examined whether M6a also forms homo- and/or hetero-dimers
(oligomers) in HEK293 cells. As shown in Figure 4.6B, M6a formed  homo-dimers (or
oligomers) with itself, and hetero-dimers (or oligomers) with M6b, but not with DM20.
The formation of homo-dimers of M6a was further confirmed biochemically in Western
blot experiment as shown in Figure 4.6C. These results indicated that M6a selectively
dimerizes with M6a and M6b, but not with DM20.
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Figure 4.6. Formation of dimers of MOR1 or M6a. A. Cells were transiently cotransfected in
different combinations with GFP or Rluc (negative control), Rluc- or GFP-tagged MOR1 as shown in
the graph. GFP-Rluc was used as positive control. B. Cells were transiently cotransfected with amino-
terminally Rluc-tagged M6a in combination with GFP (negative control), amino-terminally GFP-tagged
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M6a, M6b or DM20. Cells were harvested 45 h post-transfection. The energy transfer was measured as
described under “Methods”. The results in A and B represent mean ± SEM of 3-5 independent
experiments performed in duplicate. Asterisk indicates an extremely significant difference (P<0.001,
compared with negative control) analyzed by one-way ANOVA followed by Bonferroni test. C. Cell
lysate protein from HEK293 cells with expression of Myc-M6a (M6a), or without expression of Myc-
M6a (CK), were extracted, and were electrophoretically separated, transferred to nitrocellulose
membrane and detected with monoclonal anti-Myc antibody. The mobility of molecular mass standards
(in kDa) is indicated to the left. Two additional experiments gave similar results.
4.7 Co-expression of MOR1 and M6a in rat brain
Co-localization is a prerequisite of protein-protein interaction under physiological
conditions. Since an anti-M6a antibody for immunohistochemical studies is currently
unavailable, we firstly evaluated the co-expression of MOR1 and M6a mRNAs using in
situ hybridization techniques. In situ hybridization technique can be used to visualize cells
that synthesize the respective proteins. Previous researchers reported that there is a good
correlation between the distribution of mRNA and protein of MOR1 in the central nervous
system (Delfs et al., 1994; Mansour et al., 1994, 1995a, 1995b; Stumm et al., 2004). In
addition, the distribution of the M6a antigen has been demonstrated to fit well with the
pattern of M6a mRNA expression (Yan et al., 1993, 1996; Roussel et al., 1998).
As depicted in Figure 4.7A, MOR1 mRNA was detected in many areas of rat brain.
High expression of MOR1 mRNA was detected in the medial habenular nuclei and
thalamic nuclei (Figure 4.7, A1-A2), including the mediodorsal thalamic nucleus, the
central medial thalamic nucleus and intermediodorsal thalamic nucleus. MOR1 mRNA was
also found in numerous scattered cells of the cerebral cortex (Cx), hippocampal formation
(Hi), caudate putamen (CPu) and globus pallidus (GP). This expression pattern of MOR1
mRNA was in line with previous reports showing that MOR1 was expressed in neurons
(Delfs et al., 1994; Arvidsson et al., 1995; Mansour et al., 1994, 1995a). High expression
of M6a mRNA was detected in many regions (Figure 4.7B), including cerebral cortex,
hippocampus, thalamus and striatum. The expression of M6b mRNA was detected in
almost all regions (Figure 4.7C), including both white and gray matters in rat brain. The
expression of PLP/DM20 mRNA was much higher when compared with that of M6a and
M6b. PLP/DM20 mRNA was distributed in typical areas of oligodendrocyte, including the
corpus callosum and fimbria/fornix (Figure 4.7D). This observation was in agreement with
previous reports showing that M6a was expressed in neurons, and PLP/DM20 was limited
to oligodendrocytes whereas M6b was expressed in both of neurons and oligodendrocytes
in central nervous system (Yan et al., 1993, 1996). It is therefore plausible to predict a co-
expression between MOR1 and M6a, but not between MOR1 and PLP/DM20 in rat brain.
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Figure 4.7. Expression patterns of MOR1, M6a, M6b and PLP/DM20 mRNAs. Rat brain sections
were hybridized with [35S]-labeled antisense probes. Low-power X-ray film autoradiographs through the
forebrain at the level of bregma –1 mm (A1-D1, left panel) and –3 mm (A2-D2, middle panel) after in
situ hybridization were shown for MOR1 (A), M6a (B), M6b (C) and PLP/DM20 (D) mRNAs.
Darkfield micrographs of the hippocampal formation in a higher magnification were shown in A3-D3.
A1-A3: MOR1 mRNA was expressed by numerous scattered neurons in many areas, including cerebral
cortex, all layers of the hippocampal formation and striatum. Highly expressed MOR1 was detected in
thalamic nuclei. B1-B3: M6a mRNA was most prominent in cerebral cortex and hippocampus. In
addition, numerous cells expressing M6a mRNA were detected in striatum and thalamus. C1-C3:
Moderate expression of M6b mRNA was seen in many regions of gray and white matters. D1-D3.
PLP/DM20 mRNA was strongly expressed in typical regions of oligodendrocytes. Note: 1) CA1 (CA2,
CA3): CA1 (CA2, CA3) field of the hippocampus; cc: corpus callosum; CPu: caudate putamen; Cx:
cerebral cortex; DG: dentate gyrus; ff: fimbria/fornix; fi: fimbria hippocampus; GP: globus pallidus; Hi:
hippocampus formation; Th: thalamus. 2) The white dashed rectangles with number shown in A2 and
A3 were the similar regions for the representative observation in double in situ hybridization later
(Figure 4.8). 3) Calibration bar in X-ray film autoradiographs (A1-D1, A2-D2): 8 mm; in darkfield
micrographs (A3-D3): 1 mm.
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Figure 4.8. Co-expression pattern of MOR1 with M6a, M6b or PLP/DM20 in rat brain. A-B: In
thalamus, wide expression of MOR1 and M6a mRNAs were detected, respectively. C :  As a
representative example, no in situ signal was detected using a [35S]-labeled sense probe of M6a. D: In
thalamus, most cells co-expressed both of MOR1 and M6a mRNAs. E-F: In thalamus, all MOR1
positive cells were M6b or PLP/DM20 negative, respectively. G: In cortex, all MOR1 positive cells
were M6a positive whereas most M6a positive cells were MOR1 negative. H: In pyramidal cell layer, it
appeared that few MOR1 positive cells were M6a positive. In the stratum radiatum (Rad) and oriens
layer (Or), co-expression of MOR1 and M6a was often. I: In globus pallidus, co-expression of MOR1
and M6a was undetectable. Note that: 1) [35S]-labelled mRNAs were shown as dark emulsion grains,
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and DIG-labelled mRNAs were detected as chromogenic reaction products. 2) The investigated regions
of D-F, G, I and H were from region 1, 2, 3 and 4, respectively in Figure 4.7A. 3) Cellular nuclei in A-C
were stained with cresyl violet. 4) As an example, MOR1-M6a co-expressive cells (arrowhead), MOR1-
positive cells (arrow) were shown in the images. The representative expressions of M6a, M6b and
PLP/DM20 were shown as green, white and red asterisk, respectively. Dark or red dashed circles
showed cell size. cc, corpus callosum. 3V, 3rd ventricle. Calibration bar: A-C, 100 µm; D-F, 20 µm; G-I,
40 µm.
The effect of opiate drugs depends on the presence of opioid receptors in specific
brain regions. Both thalamus and cortex are significantly involved in analgesia and
processing of pain information (Davis et al., 1998; Peyron et al., 2000; Sim-Selley et al.,
2000; Zubieta et al., 2001; Maher et al., 2005). In particular, the thalamus is a main neural
substrate in nociceptive pathways (Craig et al., 1994; Rausell et al., 1998; Ko et al., 2003).
Both MOR1 and M6a mRNAs were expressed in large proportions of thalamic cells
(Figure 4.8, A-B), suggesting the co-expression of the µ-opioid receptor and M6a in the
same cell. As predicted, virtually all MOR1-positive cells expressed M6a mRNA, and
most M6a-expressing cells were MOR1-positive in many thalamic nuclei (Figure 4.8D). In
cerebral cortex, expression of M6a mRNA was more abundant than that of MOR1 mRNA.
Cell counting of double- and single-labelled cells revealed that almost all of MOR1-
positive cells expressed M6a mRNA whereas only a subpopulation of M6a-positive cells
were MOR1-positive (Figure 4.8G).
We also investigated the co-expression pattern of MOR1 with M6a in other brain
regions. Only very few of cells co-expressed MOR1 and M6a mRNAs in granule cells of
dentate gyrus and the pyramidal cell layer of hippocampus (Figure 4.8, H). In the other
layers of hippocampal formation, including the stratum radiatum and oriens layer, co-
expression of MOR1 and M6a mRNAs was frequent (Figure 4.8, H). In globus pallidus, all
cells expressing MOR1 mRNA were M6a negative (Figure 4.8, I).
In marked contrast to the frequent co-expression between MOR1 and M6a mRNAs,
co-expression of MOR1 mRNA with M6b or PLP/DM20 mRNA was undetectable in
thalamus (Figure 4.8, C and E). In fact, co-expression of MOR1 mRNA with M6b or
PLP/DM20 mRNA was not found in any region tested (data not shown).
Based on the strong interaction of MOR1 with M6a and their co-expression in rat
brain, we next investigated the potential role of M6a in MOR1 regulation.
4.8 M6a does not influence binding and inhibition of AC by MOR1 agonist
The endogenous M6a protein in HEK293 cells was undetectable using presently
available antibodies (data not shown). To elucidate the effect of MOR1-M6a interaction on
binding and signal transduction, we stably co-expressed HA-tagged MOR1 and Myc-
tagged M6a in HEK293 cells. Co-expression of HA-MOR1 and Myc-M6a was monitored
by radioligand binding assay, Western blot, and/or immunocytochemical analyses. As
shown in table 4.1, saturation binding experiments revealed no substantial differences
between MOR1 and MOR1-M6a expressing cells with respect to their affinities (KD) to
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[3H]DAMGO and their numbers of maximal binding sites (Bmax). For the functional
properties to inhibit adenylate cyclase (AC), there was no significant difference on their
maximal inhibition of 25µM forskolin-induced cAMP accumulation by 5 µM DAMGO.
These results indicated that M6a has no substantial effect on MOR1 in HEK293 cells, both
in agonist binding and maximum inhibition of adenylate cyclase.
Stable cell lines
KD
(nM)
Bmax
(pmol/mg)
Maximal inhibition of
cAMP accumulation
HA-MOR1 2.25 ± 0.10 2.68 ± 0.26 98.8 ± 0.8 %
HA-MOR1&Myc-M6a 2.17 ± 0.22 2.10 ± 0.15 96.1 ± 1.3 %
Table 4.1 Functional properties of HA-MOR1 and HA-MOR1&Myc-M6a. The KD and Bmax for the
binding of [3H]DAMGO to MOR1 in stable cell line expressing amino-terminally HA-tagged MOR1
with or without co-expression of amino-terminally Myc-tagged M6a in HEK293 cells were determined
by Scatchard analyses. The effect of 5 mM DAMGO on forskolin-stimulated cAMP accumulation was
determined as described under “Methods.” Values shown are the mean ± SEM of 4-5 independent
experiments.
4.9 M6a augments µ-opioid receptor trafficking
Firstly, we investigated the subcellular distribution of M6a. As depicted in Figure
4.9, M6a was localized both at plasma membrane and in cytosolic vesicles of stably
transfected HEK293 cells expressing amino-terminally Myc-tagged M6a. Interestingly,
after exposure to monensin, an inhibitor of vesicle recycling, M6a accumulated in cytosolic
vesicle-like compartments. Moreover, hypertonic sucrose (a blocker of protein
internalization via clathrin-coated pits) significantly fixed M6a at the plasma membrane.
These observations implied that M6a does internalize and recycle constitutively.
Figure 4.9. Intracellular trafficking of the membrane glycoprotein M6a. HEK293 cells stably
expressing Myc-M6a were either not exposed (control) or exposed to 50 µM monensin or 400 mM
sucrose for 3 hours at 37°C. Cells were subsequently fixed, and the distribution of M6a were examined
by confocal microscopy as described under “Methods”. Representative images from two independent
experiments are shown. Scale bar, 16 µm.
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Figure 4.10. Subcellular distribution of HA-MOR1 and/or Myc-M6a. HEK293 cells stably
expressing HA-MOR1 and/or Myc-M6a were either not exposed (A-C, control) or exposed to 400 mM
sucrose for 3 hours (D) or 50 µM monensin for 30 minutes (E) at 37°C. Cells were subsequently fixed,
and the receptor and M6a were examined by confocal microscopy as described under “Methods”. Note
that: 1) In untreated cells expressing MOR1 or M6a alone, MOR1 (A) was almost exclusively confined
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to the plasma membrane whereas M6a (B) was distributed not only at plasma membrane, but also in
cytoplasm. 2) In untreated cells co-expressing MOR1 and M6a, MOR1 (C1) was distributed not only at
plasma membrane, but also in cytoplasm. 3) MOR1 showed strict co-localization with M6a (C3 and
E3). 4) Sucrose decreased the accumulation of MOR1 and M6a in cytoplasm (D3), whereas monensin
enhanced this accumulation (E3). 4) The punctual staining of MOR1 receptors (D) was partly due to
high hypertonicity of sucrose. Representative images from two independent experiments are shown.
Scale bar, 16 µm.
Next, we investigated whether the constitutive internalization and recycling of M6a
(Figure 4.9) influences the intracellular trafficking of MOR1. In HEK293 cells stably
expressing Myc-tagged M6a alone (Figure 4.10, B), M6a was localized both at the plasma
membrane and in endosome like structures of the cytoplasm. In stably transfected HEK293
cells expressing amino-terminally HA-tagged MOR1 alone (Figure 4.10, A), almost all of
receptors were localized at the plasma membrane with some occasional
immunofluorescence within the intracellular compartments of the cells. However, in cells
co-expressing HA-MOR1 and Myc-M6a, a significant immunoreactivity of receptors was
found in endosome like structures in cytoplasm in addition to the distribution at the plasma
membrane (Figure 4.10, C1), and showed a strict co-localization with Myc-M6a (Figure
4.10, C2-C3). M6a shows high homology with the proteolipid protein (PLP) (Yan et al.,
1993). Over-expression of PLP has been shown to induce an abnormal accumulation of
PLP and cholesterol in the late endosomal/lysosomal compartments (Simons et al., 2002).
Analogously, it should be possible that over-expression of M6a induced an abnormal
accumulation of receptors in cytoplasm. After exposed of MOR1 and M6a co-expressing
cells to sucrose, both MOR1 and M6a were mainly localized at the plasma membrane
(Figure 4.10, D). The treatment of monensin markedly enhanced the accumulation and co-
localization of both MOR1 and M6a in cytoplasm (Figure 4.10, E as compared to C).
These findings indicate that the M6a-mediated accumulation of MOR1 in cytoplasm is the
result of an enhanced constitutive internalization and recycling of MOR1.
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Figure 4.11. Co-internalization and co-localization of HA-MOR1 and Myc-M6a. Cells expressing
HA-MOR1 and/or Myc-M6a were grown on poly-L-lysine coated glass coverslips. Receptor and/or
M6a were surface-labeled at 4 °C with anti-HA and/or anti M6a antibodies. Subsequently, cells were
either not exposed or exposed to 10 µM DAMGO at 37°C for 30 min. After fixation, MOR1 and M6a
were detected by confocal microscopy as described under “Methods”. Note that: 1) M6a augmented the
MOR1 constitutive internalization (B1 as compared to B4). 2) Either in untreated cells or agonist-
treated cells, MOR1 showed co-internalization and co-localization strictly with M6a (B3 and C3). 3)
M6a enhanced agonist-induced internalization of MOR1 (C1 versus C4). Shown are representative
results from one of three independent experiments. Scale bar, 16 mm in A, and 20 mm in B and C.
The anti-HA antibody recognizes the HA-epitope tag located in the extracellular N-
terminal tail of HA-MOR1, and the anti-M6a monoclonal antibody recognizes the
extracellular loop of the M6a antigen. These properties of the antibodies make it possible
to specifically label MOR1 and/or M6a at the surface of living cells. Without membrane
permeabilization, MOR1 and/or M6a at the cell surface can be specifically labeled using
anti-HA and/or anti-M6a antibodies at 4 °C. As shown in Figure 4.11A, receptor and/or
M6a were exclusively confined to the plasma membrane at low temperature (4 °C), which
prevents the endocytosis of MOR1 and M6a. Incubation of the HEK293 cells expressing
HA-MOR1 alone at 37 °C for 30 min did not induce substantial receptor internalization
(Figure 4.11, B4). In remarkable contrast, in cells co-expressing M6a, the anti-HA and
anti-M6a immunofluorescences were detected in cytoplasm (Figure 4.11, B1), confirming
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that M6a-mediated intracellular accumulation of MOR1 (Figure 4.10C) was due to M6a-
augmented receptor internalization. M6a showed co-internalization and co-localization
during the constitutive internalization of MOR1 (Figure 4.11, B2-B3). Furthermore, after
30 min of 10 µM DAMGO treatment, cells co-expressing MOR1 and M6a exhibited an
enhanced internalization (Figure 4.11, C1) as compared with cells expressing the receptor
alone (Figure 4.11, C4). The agonist-induced co-internalization of M6a and MOR1 was
evident by its strict co-localization within the intracellular compartments (Figure 4.11, C3).
This indicated that M6a enhances the internalization of MOR1. In addition, like opioid
pepide DAMGO, similar observations were also found when cells were treated with
alkaloid agonist etorphine (data not shown).
4.10 Quantitative analysis of µ-opioid receptor trafficking
Analysis using confocal microscope indicated that M6a enhances both constitutive
and agonist-stimulated internalization of MOR1. In addition, we quantified the rate of
MOR1 trafficking by ELISA. As expected, there was an enhanced constitutive
internalization of MOR1 in cells co-expressing M6a ( 9.4 ± 0.5 % versus 26.3 ± 1.4 % for
MOR1 and MOR1-M6a, respectively, Figure 4.12, left panel). In the presence of 1µM
DAMGO for 30 min, an augmented rate of agonist-mediated receptor internalization by
M6a was also detected (32.4 ± 2.7  % versus 47.8 ± 1.0 %   for MOR1 and MOR1-M6a,
respectively, Figure 4.12, left panel). In addition, in the presence of etorphine, M6a-
augmented MOR1 internalization was also observed (data not shown).
The recycling rate of internalized receptors was examined using a modified form of
ELISA previously described for estimating receptor internalization (Koch et al., 2003). The
incubation of cells in the presence of 10 µM etorphine for 2 h led to an agonist-induced
internalization to a steady-state level in cells both with and without co-expression of M6a.
After receptor internalization, the agonists were washed out and then cells were incubated
in agonist free medium for receptor recycling. In this experiment, the antagonist naloxone
was added into incubation medium to block further endocytosis. As shown in Figure 4.12
(right panel), the recycling rate was estimated as a percent of the recycled receptors to
endocytosed receptors. In cells co-expressing M6a, about 32% of endocytosed receptors
was recycled after 30 min of agonist withdrawal. By contrast, in cells expressing receptor
alone, only about 9% of internalized receptors was recycled. After 60 min of agonist
withdrawal, over 30% of internalized receptors was recycled in both cell lines.
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Figure 4.12. Quantitative analysis of MOR1 trafficking. Left panel. For the analysis of receptor
internalization, cells expressing HA-MOR1 alone or co-expressing with Myc-M6a were surface-labeled
with anti-HA antibody at 4°C for 1.5 h. Subsequently, cells were either not treated or treated with 1 µM
DAMGO for 30 min, and then fixed. Receptor internalization, quantified as the percent loss of cell
surface receptors, was measured by ELISA as described under “Methods”. Right panel. For the
analysis of receptor recycling, cells were first exposed to 10 µM etorphine for 2 h to drive receptor
internalization to a steady-state level. After agonist washout, cells were exposed to 10 µM naloxone for
30 and 60 min. Afterwards, cells were chilled with 4°C PBS to stop receptor trafficking. Receptors were
surface-labeled with anti HA antibody at 4°C for 2 h. Un-bound antibodies were washed out, cells were
then fixed and the surface receptors were quantified as described above. The recycling rate was
estimated as a percent of recovered surface receptors to internalized receptors. Data are presented as
means ± SEM of 3-5 independent experiments performed in triplicate. Asterisk indicates an extremely
significant difference (p<0.001) between MOR1 and MOR1-M6a expressing cells (One-way ANOVA
followed by Bonferroni test).
These results are in excellent agreement with the observations by confocal
microscopy, and provide convincing evidence that M6a enhances both internalization and
recycling of the µ-opioid receptor in HEK293 cells.
4.11 Expression of M6a mRNA in HEK293 cell
In earlier reports, M6a antigen was detected at the apical surfaces of epithelial cells
in mouse kidney (Lagenaur et al., 1992). In the human kidney cell line (HEK293 cells), we
were unable to detect the endogenous M6a using presently available anti-mouse M6a
antibodies (data not shown). This could be due to the low expression of M6a and/or the
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low avidity of the available antibodies. Using RT-PCR, a high sensitive method, we were
able to amplify and sequence the transcript of M6a in HEK293 cells.
Figure 4.13. Neucleotide sequence and deduced amino acid sequence of M6a cDNA from HEK293
cells. The nucleotide sequence and corresponding translated amino acid sequence of the M6a cDNA
from HEK293 cells are shown. The nucleotide and amino acid residues were numbered on the left and
right, respectively. In comparison to the human M6a cDNA (Olinsky et al., 1996), the difference in
nucleotides and deduced amino acids were shown in bold, italic and underlined. Note that it is
impossible that this cDNA derives from the genomic DNA because there is no intron inside.
Analysis of cDNA sequence of HEK293 M6a (Figure 4.13) revealed a 99%, 93%,
91% homology to the reported M6a nucleotide sequence of human (Olinsky et al., 1996;
GI:21314625), mouse (Yan et al., 1993; GI:31981997) and rat (Mukobata et al., 2002;
GI:57527945), respectively. In comparison with the reported human M6a protein sequence,
there are only two amino acids different (Figure 4.13). This difference might be due to
gene polymorphisms, although sequencing errors can not be completely excluded. The
existence of M6a in HEK293 cells suggests that endogenous M6a can play a role in the
intracellular trafficking of MOR1 in these cells.
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4.12 The effect of M6a dominant negative mutants on MOR1 internalization
As shown above (Figure 4.4C), both the amino terminal truncation mutant (amino
acids 1-108) and the truncation mutant (amino acids 129-255) of M6a interact with the full
length of MOR1 (Figure 4.4C). This finding led us to test whether these truncations act as
dominant negative mutants of MOR1 internalization in HEK293 cells with endogenously
expressed M6a.
Figure 4.14. Effect of M6a dominant negative mutants on MOR1 internalization. HEK293 cells
stably expressing HA-MOR1 were transiently transfected with plasmids encoding GFP-M6a, GFP-
M6a(amino acids 1-108) or GFP-M6a(amino acids 129-255) as described under “Methods”. About 60 h
after transfection, cells were pretreated using 50 µM monensin for 30 min and then were exposed to 10
µM DAMGO in the presence of 50 µM monensin for another 30 min at 37°C. Cells were subsequently
fixed, and the receptor was immunostained using rabbit anti-HA antibody and Cy3 conjugated anti-
rabbit antibody. The GFP signal (green) and Cy3 signal (red) were taken by confocal microscopy.
Representative images from two independent experiments are shown. Scale bar, 8 µm.
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In cells co-expressing GFP-tagged M6a, a marked DAMGO-induced internalization
of MOR1 was seen (Figure 4.14, upper panel). This was also confirmed by quantitative
ELISA (data not shown). However, after over-expression of GFP-tagged truncation
mutants (amino acids 1-108 and 129-255) of M6a, DAMGO-induced MOR1-
internalization was almost blocked completely whereas receptors in adjacent cells that did
not express these mutants internalized in response to agonist (Figure 4.14, middle and
lower panel). It is likely that these mutants can function as dominant negative mutants to
compete for binding of endogenous M6a to MOR1, and thus impairs receptor
internalization. This finding further supports a physiological role of M6a in MOR1
internalization.
4.13 M6a increases accumulation of MOR1 and DOR1 in recycling endosomes
Next, we examined whether M6a modulates the trafficking pathway and post-
endocytic sorting of opioid receptors. We carried out immunocytochemistry to estimate
whether co-internalized receptor and M6a would be associated with the endocytic vesicles
that can be identified by Alexa Fluor 488-labeled transferrin, a well-established marker of
early and recycling endosomes (Hopkins and Trowbridge, 1983; Dunn et al., 1989; Tsao
and von Zastrow, 2000).
Surface opioid receptors (MOR1, DOR1) and M6a were labeled by exposing intact
cells to appropriate specific antibodies. When these cells were simultaneously incubated
with selective agonists and Alexa Fluor 488-conjugated transferrin for 30 min, a high
degree of co-localization among opioid receptor, M6a and endocytic transferrin was
detected (Figure 4.15A), indicating that the opioid receptors and M6a co-internalize into
early endosome via the same trafficking pathway as the transferrin receptor. Moreover,
when cells were first incubated with 10 µM DAMGO to initiate a 30-min pulse of receptor
internalization, and then chased for an additional 20 min in the presence of labeled
transferrin in agonist-free medium, a high degree of co-localization among the pulse of
internalized MOR1, M6a and the recycling endosome marker transferrin was still observed
(Figure 4.15B, upper panel). Unexpectedly, in cells co-expressing M6a, co-internalized
DOR1 still co-localized with transferrin whereas internalized DOR1 was mainly sorted
into the other compartments in adjacent cells without co-expression of M6a (Figure 4.15B,
lower panel). This demonstrated that over-expression of M6a did not change MOR1
trafficking pathway but enhanced post-endocytic sorting of receptors for the recycling
pathway. Consistent with this, after agonist-induced endocytosis, MOR1 is sorted into
recycling endosome for recycling whereas DOR1 is mainly targeted to lysosomes for
degradation (Tanowitz and von Zastrow, 2003; Wang et al., 2003). This suggested that M6a
directs internalized opioid receptors into recycling endosomes during receptor post-
endocytic sorting.
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Figure 4.15. Trafficking pathway of MOR1, DOR1 and M6a. Stable HA-DOR1 cells transiently
transfected with pCMV-Myc-M6a plasmid, and cells stably co-expressing HA-MOR1 and Myc-M6a
were used. A. Co-internalization of MOR1/DOR1, M6a and transferrin. Cells were surface-labeled and
exposed to 10 µM DAMGO (or DPDPE) and 5 µg/ml Alexa Fluor 488-conjugated transferrin for 30
min. Confocal microscopy was used to examine the internalization of antibody-labeled receptors, M6a
and Alexa Fluor 488-conjugated transferrin, as described under “Methods”. B. Post-endocytic sorting of
internalized opioid receptors and M6a. Confocal microscopy of triple labeled cells was used to examine
the co-localization of a 30-min agonist pulse of antibody-labeled receptors and M6a followed by a 20-
min chase with transferrin in the absence of agonist, as described under “Methods”. Note that: Overlap
of MOR1 (blue), M6a (red) and transferrin (green) was denoted by the white vesicular structures
visualized in merged image. Overlap of receptor with M6a generated magenta; Overlap of receptor with
transferrin generated cyan; and Overlap of M6a with transferrin generated yellow. Representative
images from one of three independent experiments are shown. Scale bar, 16 µm.
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4.14 M6a attenuates down-regulation of the µ-opioid receptor
Down-regulation of opioid receptors in response to chronic opioid treatment is a
long-term adaptive process, which results from the proteolytic degradation of internalized
receptors. The present studies provided evidences that over-expression of M6a augments
the recycling of µ-opioid receptors (Figure 4.12). The M6a-enhanced receptor recycling
might decrease receptor endosomal sorting to lysosomes for degradation, and thus decrease
receptor down-regulation.
As expected, and consistent with the observation that M6a augmented receptor
recycling (Figure 4.12), agonist-induced down-regulation of MOR1 was significantly
reduced in cells with co-expression of M6a. After an extended exposure (16 hours) to
DAMGO, we observed that only 25% of MOR1 were downregulated in cells co-expressing
MOR1 and M6a in contrast to the 42% down-regulation in cells expressing MOR1 alone
(Figure 4.16). This is in agreement with the hypothesis that M6a-augmented receptor
recycling decreases receptor degradation in lysosomes, and thus reduces receptor down-
regulation.
Figure 4.16. Effect of M6a on MOR1 down-regulation by DAMGO. Cells stably expressing HA-
MOR1 with and without Myc-M6a were incubated at 37°C for 16 hours in the presence or absence of 5
µM DAMGO. The amount of total MOR1 was examined by membrane binding assay as described
under “Methods”. The total receptor without DAMGO treatment was set as 100% (Control). Values
represent mean ± SEM of 3-5 independent measurements performed in triplicate. Asterisk indicates a
significant difference (p<0.05) between MOR1 and MOR1-M6a expressing cells (One-way ANOVA
followed by Bonferroni test).
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4.15 M6a decreases agonist-induced desensitization of the µ-opioid receptor
Since receptor trafficking affects agonist-induced desensitization of the µ-opioid
receptor, we investigated whether the observed effects of M6a on µ-opioid receptor
trafficking influences agonist-induced MOR1 desensitization.
Figure 4.17. The effect of M6a on DAMGO-induced µ-opioid receptor desensitization. Cells stably
expressing HA-MOR1 with and without Myc-M6a were exposed to 5 µM DAMGO in the presence or
absence of 50 µM monensin for the indicated time periods. After removal of the preincubation medium,
the cells were treated with forskolin (25 µM) or forskolin (25 µM) plus DAMGO (5 µM) for 15 min,
and cAMP levels were determined as described under “Methods”. Values represent mean ± SEM of 3-6
independent measurements performed in duplicate. Double paragraph indicate a very significant
difference (p<0.01) in the absence of monensin between MOR1 and MOR1-M6a expressing cells, and
triple asterisks indicate an extremely significant difference (P<0.001) in MOR1-M6a co-expressing cells
compared with the absence of monensin (One-way ANOVA followed by Bonferroni test).
Cells expressing HA-MOR1 with and without Myc-M6a were pre-incubated with 5
µM DAMGO for various time periods followed by the measurement of agonist-induced
inhibition of forskolin-stimulated cAMP accumulation. Receptor desensitization was
monitored by the decreased ability of the MOR1 agonist to inhibit forskolin-stimulated
adenylate cyclase activity, which represents loss of signaling caused by both receptor
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uncoupling and internalization. As shown in Figure 4.17, prolonged exposure to the µ-
opioid receptor selective agonist DAMGO led to a time-dependent decrease in the
inhibition of cAMP accumulation. During the first hour of agonist treatment, there was no
significant difference in MOR1 desensitization with and without co-expression of M6a.
However, after the prolonged agonist treatment, cells co-expressing MOR1 and M6a
exhibited a slower desensitization rate as compared to cells expressing MOR1 alone. After
6 hours of agonist exposure, about 40% loss of DAMGO activity was observed in cells
expressing MOR1 alone, whereas in cells co-expressing M6a only about 25% loss in
DAMGO activity was observed. In general, receptor internalization is expected to
contribute to receptor desensitization. However, in case of MOR1, receptors are recycled
back to the plasma membrane after internalization; the reactivated receptors, in turn,
contribute to receptor resensitization, which partially reverses ongoing receptor
desensitization (Koch et al., 1998, 2001, 2004, 2005; Law et al., 2000a; Qiu et al., 2003;
Beyer et al., 2004). According this hypothesis, the lower receptor desensitization in M6a-
expressing cells is most likely explained by the M6a-augmented receptor recycling.
To prove this hypothesis, we tested the effect of monensin, a blocker of receptor
recycling, on receptor desensitization. In fact, as depicted in Figure 4.17, application of
monensin in cells co-expressing MOR1 and M6a markedly enhanced DAMGO-induced
desensitization of MOR1 in these cells. This is in clear agreement with the notion that the
enhanced MOR1 recycling caused by M6a is responsible for the decreased MOR1
desensitization, since it can be reversed by the recycling blocker monensin.
Peptide agonists, such as DAMGO, induce a pronounced endocytosis of the µ-opioid
receptor, whereas many clinical alkaloid drugs (e.g. morphine) are very weak in their
ability to promote receptor internalization (Koch et al., 2005). We analyzed whether
agonist-induced receptor desensitization would be a result of agonist-mediated receptor
internalization by comparing DAMGO and morphine-induced receptor desensitization.
As depicted in Figure 4.18, a small but clear receptor desensitization was detected
after pretreatment with morphine for 1 hour. At that time, the degree of desensitization
after morphine was higher than that after the receptor internalizing opioid DAMGO
(Figure 4.18). The recycling blocker monensin which caused a marked increase in the
desensitization of the receptor-internalizing agonist DAMGO did not significantly change
the desensitization of the non-internalizing agonist morphine (Figure 4.18). After a longer
time period (4h), morphine induced a greater receptor desensitization than DAMGO (42.4
± 3.3% versus 18.6 ± 3.0% for morphine and DAMGO, respectively) (Figure 4.18). Again,
in contrast to the desensitization after DAMGO, monensin did not significantly affect the
extent of receptor desensitization after morphine at this time-point. These findings show
that the morphine-induced MOR1 desensitization does not require internalization and
reflects most likely uncoupling of the receptors from the G-proteins. Internalization is,
therefore, not a prerequisite for agonist-induced desensitization of MOR1.
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Figure 4.18. Comparison of DAMGO- and morphine-induced MOR1 desensitization. Cells stably
co-expressing HA-MOR1 and Myc-M6a were treated with 5 µM DAMGO or morphine in the presence
or absence of 50 µM monensin for 1 and 4h. The cAMP levels were determined as described under
“Methods”. Maximum agonist-induced inhibition of cAMP accumulation without agonist preincubation
was defined as 100%. Values represent mean ± SEM of at least 3 independent measurements performed
in duplicate. Double asterisks indicate a very significant difference (p<0.01), and triple asterisks
indicate an extremely significant difference (P<0.001) as compared in this graph (One-way ANOVA
followed by Bonferroni test).
4.16 Role of M6a in MOR1 internalization in primary cultured neurons
We have demonstrated the effect of M6a on MOR1 internalization and
desensitization in HEK293 cells. MOR1 and M6a proteins are mainly expressed in neurons
(Mansour et al., 1995b; Roussel et al., 1996; Drake and Milner, 1999; Kaplan et al., 2004).
Non-neuronal cell models might not be appropriate for studying opioid receptor regulation
owing to their potential lack of crucial components of regulatory pathway that exist in
native neurons. Therefore, we investigated whether the observed co-localization and co-
internalization of MOR1 and M6a in HEK293 cells also occur in primary cultured neurons.
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Figure 4.19. Subcellular distribution of HA-MOR1 and Myc-M6a in co-transfected primary
cultured neurons. Newly prepared cortical cells (E17) were grown on poly-D-lysine-coated glass
coverslips for about 100 hours, and then subjected to the co-transfection with pCMV-HA-MOR1 and
pCMV-Myc-M6a plasmids. 40 hours after transfection, cells were fixed. HA-MOR1 and Myc-M6a
were detected using anti-HA and anti-Myc antibodies as described under “Methods”. The overlay image
was shown in a higher magnification image (4 folds in comparison with single image). The green
fluorescence (Cy2) represents the distribution of HA-MOR1, and the red fluorescence (Cy3) for Myc-
M6a, the yellow for overlay. Shown is a representative result from one of three independent
experiments.
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Figure 4.20. The effect of M6a on MOR1 internalization in co-transfected primary cultured
neurons. Newly prepared cortical cells (E17) were grown on poly-D-lysine-coated glass coverslips for
about 100 hours, and then subjected to transfection with HA-MOR1 and/or M6a expressing plasmids.
40 hours after transfection, the surface HA-MOR1 and/or M6a were labeled at 4 °C with anti-HA and/or
anti M6a antibody for 1 hour. Subsequently, cells were incubated in the presence or absence of 10 µM
DAMGO at 37°C for 30 min, and then fixed immediately. Distribution of HA-MOR1 and/or M6a was
detected by confocal microscopy as described under “Methods”. In cells transiently expressing HA-
MOR1 alone (A-B), the constitutive and agonist-induced internalization of HA-MOR1 were shown in
A1 and B1, respectively. Part of the processes in A1 and B1 was shown in a higher magnification image
(A2 and B2, respectively). In cells transiently co-expressing HA-MOR1 and M6a, the agonist-induced
co-internalization of HA-MOR1 and M6a was shown in C. The overlay image of C1-C2 was shown in
large magnification (4 folds versus C1 or C2). Note that: 1) HA-MOR1 and M6a are co-localized and
co-internalized in transfected neurons. 2) M6a enhances agonist-induced internalization of HA-MOR1
in the cell body (C as compared to B). Shown are representative results from one of two independent
experiments.
Since the endogenous µ-opioid receptor and the membrane glycoprotein M6a were
under detectable level using available anti-MOR1 and anti-M6a antibodies in primary
cultured cortical neurons (E17), we introduced exogenous MOR1 and M6a by transient
transfection. As depicted in Figure 4.19, a remarkable co-localization between MOR1 and
M6a was observed, both in the cell body and processes of primary cultured neuron
transiently co-expressing HA-MOR1 and Myc-M6a.
To examine the internalization of MOR1 and/or M6a directly, we performed surface-
labelling using anti-HA and/or anti-M6a antibodies to observe the internalization of surface
MOR1 and/or M6a proteins. In cells transiently expressing HA-MOR1 alone, a
constitutive internalization of receptors was hardly visible (Figure 4.20, A). However, 30
minutes after the incubation of 10 µM DAMGO, a clear agonist-mediated internalization
of receptors could be detected (Figure 4.20, B). There was a pronounced internalization of
the receptors in the processes of the neurons (Figure 4.20, B2) whereas only a few of
receptors in the cell body were endocytosed (Figure 4.20, B1). In contrast, in cells co-
expressing MOR1 and M6a, 10 µM DAMGO stimulated a remarkable co-internalization of
the receptor and M6a in both of the cell body and processes (Figure 4.20, C1-C3). This
observation provided the direct evidence that MOR1 and M6a co-internalized in
transfected neurons, and M6a might enhance the receptor internalization. This is in line
with the observed co-localization and co-internalization of MOR1 and M6a in HEK293
cells (Figure 4.11).
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4.17 M6a attenuates MOR1 desensitization in primary cultured neurons
Next, we examined whether the M6a effect on receptor desensitization in the
HEK293 cell model is physiologically relevant to native neurons.
As shown in Figure 4.21, DAMGO had no significant effect on forskolin-mediated
cAMP accumulation in primary cultured cortical neurons. This suggested that the number
of endogenous µ-opioid receptors in the cultured cortical neurons is too small to cause a
significant decrease in cAMP levels. Thus, cortical neurons were transfected with MOR1
and M6a. In both of MOR1 and MOR1-M6a transfected cortical neurons, 10 µM DAMGO
generated about 25% inhibition of forskolin-induced cAMP accumulation (Figure 4.21).
This indicated that M6a has no effect on the ability of MOR1 to inhibit adenylate cyclase.
Figure 4.21. M6a does not influence inhibition of adenylate cyclase by MOR1 agonist in co-
transfected primary cultured neurons. Newly prepared cortical neurons (E17) were transfected or not
transfected with HA-MOR1 and/or Myc-M6a plasmid using a “Rat Neuron Nucleofector Solution”, and
then seeded in poly-D-lysine-coated plate. 4-5 days after transfection, cells were treated with 5 µM
forskolin in the presence or absence of 10 µM DAMGO for 10 min. Forskolin-mediated cAMP
accumulation was determined as described under “Methods”. The cAMP accumulation in the absence of
agonist was defined as 100%. Values represent mean ± SEM of 3-4 independent measurements
performed in triplicate. Asterisk indicates a very significant difference (p<0.01) (One-way ANOVA
followed by Bonferroni test).
As shown in Figure 4.22, after 1h of 10 µM DAMGO pretreatment, there was no
significant difference in DAMGO-induced receptor desensitization betwen MOR1 and
MOR1-M6a transfected cells. In marked contrast, 4 hours after agonist pretreatment,
DAMGO-induced receptor desensitization was significantly reduced in MOR1-M6a co-
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transfected cells as compared with MOR1 transfected cells. This was in agrement with the
finding that over-expression of M6a decreased DAMGO-induced MOR1 desensitization in
HEK293 cells (Figure 4.17). Thus, the mechanisms of agonist-induced receptor
desensitization seen to be similar in HEK293 cells and primary cultured cortical neurons.
This indicates that M6a regulates the signaling of the µ-opioid receptor in native neurons.
Figure 4.22. DAMGO-induced µ-opioid receptor desensitization in transfected primary cultured
neurons. Newly prepared cortical neurons (E17) were transfected with HA-MOR1 and/or Myc-M6a
plasmids using a “Rat Neuron Nucleofector Solution”, and then seeded in poly-D-lysine-coated plate. 4-
5 days after transfection, cells were preincubated with 10 µM DAMGO for 1 and 4 h. The agonist-
induced receptor desensitization was determined as described under “Methods”. Maximum agonist-
induced inhibition of cAMP accumulation without agonist preincubation was defined as 100%. Values
represent mean ± SEM of 5-6 independent measurements performed in triplicate. Asterisk indicates a
very significant difference (p<0.01) (One-way ANOVA followed by Bonferroni test).
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5 Discussion
5.1 Interaction of the µ-opioid receptor with the membrane glycoprotein M6a
In the present study, several lines of evidences suggest a direct interaction between
MOR1 and M6a. First, the interaction between MOR1 and M6a was verified in yeast
mating and ß-galactosidase assay (previous data from our group). Second, M6a was
specifically pulled down by MOR1 in co-immunoprecipitation experiments. Third, M6a
showed a strong positive signal with MOR1 in BRET assay. Moreover, the strict co-
localization and co-internalization of MOR1 and M6a in both transfected HEK293 cells
and primary cultured neurons provided additional support for the direct interaction of
MOR1 and M6a. An interaction with MOR1 was found for M6a and M6b, but not for
DM20, another close member from the same glycoprotein family. In rat brain, the
interaction appears to be specific for M6a since double in situ hybridization revealed a co-
localization of MOR1 with M6a, but not with M6b or PLP/DM20.
To investigate the binding domain of MOR1 with M6a, we constructed a number of
truncation mutants of MOR1. Although the carboxyl terminus of MOR1 is not the direct
binding region for M6a, the interaction of MOR1B (a splice variant of MOR1) with M6a
was stronger than that with MOR1. This indicates that the carboxyl tail might influence the
interacting-conformation of the µ-opioid receptor. MOR1 and MOR1B share 100% amino
acid sequence identity up to amino acid 386 but differ by the last 12 amino acids at the
carboxyl terminus (Figure 1.2) (Zimprich et al., 1995). The carboxyl terminal tail of the µ-
opioid receptor has been shown to be an important domain for regulating receptor
trafficking (Koch et al., 1998; Wolf et al., 1999; El Kouhen et al., 2001). In fact, MOR1B
undergoes faster internalization and recycling both in the presence or absence of µ-agonist
compared with MOR1 (Koch et al., 1998). Therefore, we speculate that MOR1B may form
a highly favorable conformation to interact with M6a.
A truncated MOR1 containing the 4th and 5th transmembrane domains (amino acids
186-303) interacted with full length M6a (Figure 4.4B). Thus, it appears likely that the 4th
and 5th transmembrane domains of MOR1 are important for the interaction with M6a.
Unexpectedly, the BRET analysis revealed that M6a had two binding domains for MOR1
(Figure 4.4C). This was further supported by the finding of two dominant negative mutants
of M6a on the DAMGO-induced MOR1-internalization (Figure 4.14). Both M6a negative
mutants (amino acids 1-108 and 129-255) contain two transmembrane domains, suggesting
that two transmembrane domains of M6a are necessary to form a binding conformation in
MOR1-M6a interaction. We do not know whether under physiological condition only one
binding domain of M6a is sufficient to form a functional complex between MOR1 and
M6a. It is possible that both of them are necessary to form a functional complex. An
alternative speculation is that these two binding domains might play a role in the formation
of homo- or hetero-dimerization of GPCRs. This hypothesis is further supported by the
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findings that M6a interacts with other GPCRs, and that MOR1 forms homo-dimers in the
present studies.
5.2 Co-expression of MOR1 with members of the PLP/DM20 family in rat brain
Using specific riboprobes, different expression patterns of M6a, M6b and DM20
mRNAs were found in rat brain. Since we used a riboprobe directed against a sequence of
both DM20 and PLP, both DM20 and PLP mRNAs were measured in our experiments.
PLP/DM20 is strongly expressed in white matter (myelinated-oligodendrocyte containing)
regions, including the corpus callosum and the fimbria/fornix. There is no co-expression of
MOR1 and PLP/DM20 mRNAs. This is in agreement with previous reports showing that
MOR1 is expressed in neurons whereas PLP/DM20 is expressed in oligodendrocytes
(Arvidsson et al., 1995; Mansour et al., 1994, 1995a, 1995b; Yan et al., 1993, 1996). M6b
mRNA is expressed in both of white and gray matter areas in rat brain. In all regions, co-
expression between MOR1 and M6b is undetectable. However, we cannot exclude the
possibility that there may be a co-expression between MOR1 and M6b in other regions not
investigated.
The co-expression between MOR1 and M6a mRNAs occurs in many regions of rat
brain, including thalamus and cerebral cortex (Figure 4.8). Since the distribution of MOR1
and M6a mRNAs is correlated well with their antigens in the central nervous system (Delfs
et al., 1994; Mansour et al., 1995a, 1995b; Yan et al., 1996; Roussel et al., 1998; Stumm et
al., 2004), it is reasonable to assume that MOR1 and M6a proteins are colocalized in native
neurons, indicating an interaction between MOR1 and M6a under physiological conditions.
Interaction of receptors with scaffold, anchoring or adaptor proteins, such as M6a, is
important for internalization and post-endocytotic sorting (see reviews in Brady and
Limbird, 2002; Hall and Lefkowitz, 2002; Bockaert et al., 2004). Based on the frequent co-
expression and strong interaction between MOR1 and M6a, a potential role of M6a in the
regulation of µ-opioid receptors is reasonable.
5.3 The role of M6a in the trafficking of opioid receptors
Previous researchers have shown that the cytoplasmic tail of opioid receptors plays a
key role in receptor trafficking and signaling. Recently, a number of proteins that bind to
the cytoplasmic tail of opioid receptors have been identified by yeast two-hybrid screen,
and functionally characterized. For example, a protein interacting with DOR1, the G
protein-coupled receptor-associated sorting protein (GASP) was found to modulate the
lysosomal sorting and functional down-regulation of DOR1 (Whistler et al., 2002).
Phospholipase D2 interacts with MOR1 and accelerates agonist-induced µ-opioid receptor
internalization (Koch et al., 2003). Filamin A, a cytoskeletal protein binds to MOR1 and to
several other membrane proteins, appears to be necessary for normal MOR1 trafficking
(Onoprishvili et al., 2003). Periplakin, a cytolinker protein, interacts with MOR1 and
reduces the coupling of G proteins (Feng et al., 2003). Another protein which interacts
with MOR1 is protein kinase C-interacting protein (PKCI) which functions as a negative
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regulator in MOR1 desensitization, phosphorylation, and in mediating morphine analgesia
(Guang et al., 2004). It seems that the carboxyl tail domain of opioid receptors is the
predominant region involved in receptor regulation. If this is true, a chimeric DOR1 with
the tail of MOR1 (DOR1/MT) should have an identical phenotype as wild type MOR1.
However, this is not the case since the DOR1/MT is targeted to lysosome while MOR1 is
not (Afify et al., 1998; Wang et al., 2003). In addition, the rate and magnitude of agonist-
induced internalization of this chimera are not identical to that of the corresponding wild
type receptors (Wang et al., 2003). Moreover, C-terminally truncated MOR1 (Qiu et al.,
2003) and DOR1 (Murray et al., 1998) undergo receptor internalization. The important C-
tail motif of MOR-derived endocytic recycling sequence (MRS) in opioid receptor post-
endocytic sorting (Tanowitz and von Zastrow, 2003) fails to explain that MOR1B without
this MRS shows faster recycling compared with MOR1 (Koch et al., 1998). All these
suggest that other motifs in addition to the carboxyl tail could participate in the
intracellular trafficking of the opioid receptors. This view is further supported by recent
studies that the DOR1 carboxyl tail alone could not direct targeting of receptors to
lysosomal compartments. Instead, a di-leucine motif within the 3rd intracellular loop in
conjunction with the carboxyl tail sequence regulates the lysosomal targeting of DOR1
(Wang et al., 2003). Interestingly, although the di-leucine motif by itself could affect
DOR1 internalization kinetics, it has minimal effects on the intracellular trafficking of
MOR1 (Wang et al., 2003). These observations indicate that multiple motifs within opioid
receptors regulate the receptor trafficking.
When MOR1 and M6a are co-expressed in HEK293 cells, MOR1 shows strict co-
localization with M6a not only at the plasma membrane, but also in endosome-like vesicles
of the cytosol. This result is surprising because MOR1 is normally found mainly at the cell
surface in HEK293 cells (Koch et al., 1998, 2001, 2003). Hypertonic sucrose, an inhibitor
of receptor internalization (Heuser and Anderson, 1989), significantly inhibits M6a-
mediated distribution of MOR1 in cytoplasm, whereas monensin, an inhibitor of receptor
recycling (Stein et al., 1984; Kaiser et al., 1988), greatly augments this distribution. This
suggests a possible role of M6a in the constitutive trafficking of MOR1. Furthermore, we
directly confirmed by both confocal microscopy and quantitative ELISA that over-
expression of M6a enhances the constitutive internalization of MOR1. Thus, it is
reasonable to speculate that M6a-enhanced distribution of MOR1 in cytosolic vesicles is
due to M6a-augmented receptor internalization. M6a and proteolipid protein (PLP) belong
to the PLP/DM20 family and show high homology. However, in contrast to M6a, over-
expression of PLP induces an abnormal accumulation of PLP and cholesterol in the late
endosomal/lysosomal compartment (Simons et al., 2002).
M6a also augments agonist-stimulated internalization of MOR1. In addition, using a
pulse-chase experiment (Tsao and von Zastrow, 2000; Tulipano et al., 2004), we have
demonstrated that M6a and MOR1 share a similar trafficking pathway like transferrin
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receptors, which are rapidly recycled by recycling endosomes. Therefore, with the co-
expression of M6a, endocytosed MOR1 might be sorted preferably to recycling endosomes
for recycling. This is in line with the present findings that M6a enhances the recycling of
endocytosed MOR1, and decreases the down-regulation of MOR1.
It is well demonstrated that the internalization of GPCRs is mediated by many
biological molecules, such as kinase, b-arrestin, AP-2, clathrin and dynamin (reviewed in
Ferguson, 2001; Claing et al., 2002; Mousavi et al., 2004). In contrast, the mechanism of
post-endocytic sorting and recycling of internalized receptors is far from clear. There are
some evidences that a specific sequence present in the cytoplasmic tail of MOR1 is
necessary for rapid recycling of internalized receptors (Tanowitz and von Zastrow, 2003).
From our experiments, M6a appears to be an important protein involved in the regulation
of opioid receptor recycling.
As mentioned earlier, Whistler et al. (2002) identified a protein termed GASP (G
protein-coupled receptor-associated sorting protein) that binds preferentially to the
cytoplasmic tail of DOR1. The authors demonstrated that the strong interaction of DOR1-
GASP modulates the post-endocytic sorting between receptors destined for lysosomal
degradation and those to be recycled to the cell surface. Our data revealed that the strong
interaction of MOR1-M6a leads to the sorting of MOR1 into endosomes for recycling, and
inhibits MOR1 sorted into lysosomes for proteolytic degradation. Thus, it is reasonable to
assume that the different intracellular trafficking between MOR1 and DOR1 may be
caused by the competition between M6a and GASP during endosomal sorting of the
receptors. Consistent with this, GASP binds much less strongly to the cytoplasmic tail of
MOR1 than to DOR1 in vitro and apparently not at all in vivo (Whistler et al., 2002), and
we observed a lower interaction of M6a with DOR1 compared to MOR1 (Figure 4.5).
Therefore, a strong interaction of MOR1 with M6a might induce the rapid MOR1
recycling, whereas a strong interaction of DOR1 with GASP might target DOR1 into
lysosomes for degradation during post-endocytic sorting diagrammed in Figure 5.1.
Consistent with this hypothesis, over-expression of M6a led to the sorting of internalized
DOR1 to recycling pathway (Figure 4.15B, lower panel), and over-expression of a
dominant negative mutant of GASP inhibited the sorting of DOR1 to lysosomes (Whistler
et al., 2002).
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A. MOR1
B. DOR1
Figure 5.1. A model of the post-endocytic sorting of opioid receptors. A strong interaction between
MOR1 and M6a lead to the sorting of MOR1 into endosomes for recycling whereas a strong interaction
of DOR1 with GASP targets DOR1 into lysosomes for degradation during post-endocytic sorting. Thus,
endocytosized MOR1 predominantly recycles to cell surface when internalized DOR1 is mainly sorted
into lysosomes for proteolysis. Events unlikely to occur are indicated in gray line.
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It is generally believed that glycoproteins of the PLP/DM20 family function as
structural proteins for myelination. The present studies provide evidences supporting that
the membrane glycoprotein M6a regulates µ-opioid receptor trafficking, thereby offering a
new function of PLP/DM20 family other than its structural role in myelination. It appears
that the interaction of MOR1 with M6a might be an important step in the initiation of
clathrin-mediated receptor internalization and the following endosomal sorting of
internalized receptors. Possibly, M6a is involved in actin cytoskeleton formation and thus
induces receptor transport into cytoplasm. In support to this hypothesis, M6 protein
(M6a/M6b) was observed to be concentrated selectively in the actin-rich, leading edge
lamellipodia and philopodia of neuronal growth cones (Baumrind et al., 1992), and be
transported there by actin-dependent mechanisms (Sheetz et al., 1990). This is also in line
with the suggestion that a common feature of PLP/DM20 family is its association with the
actin cytoskeleton (Kalwy et al., 1997). Another possibility is that, M6a might change the
property of clathrin-coated vesicles and endosomes, e.g. charge and pH value, and thus
influences vesicle transportation and endosome sorting. This hypothesis is supported by the
observation that all tetraspan proteolipids, including members of PLP/DM20 family,
contribute to the formation of pore structures in a wide spectrum of cellular system
(Kitagawa et al., 1993). Moreover, Rhombex-29, a new member of PLP/DM20 family, was
suggested to be responsible for transporting +H (Shimokawa and Miura, 2000).
Taken together, we have demonstrated a function of M6a on opioid receptor
trafficking in both transfected HEK293 cells and primary cultured neurons. M6a might also
modulate the intracellular trafficking of other receptors. This view is supported by the
observation that M6a interacts to another opioid receptor (DOR1) and with the
somatostatin receptor 2A (sst2A). In addition, the interaction of M6a with sst2A is in line
with the fact that the sst2A receptor shows a rapid internalization and recycling (Tulipano
et al., 2004).
5.4 The effect of M6a on signal regulation of the µ-opioid receptor
While the functional property of M6a on MOR1 trafficking has been established
most clearly using HEK293 cells, our studies in primary cultured neurons suggest that
those also occur in native neurons. Moreover, in locus coeruleus neurons, an agonist’s
ability to produce rapid desensitization was found to correlate well with its effectiveness at
promoting receptor internalization in HEK293 cells (Alvarez et al., 2002; Bailey et al.,
2003). Thus, it is reasonable to believe that the HEK293 cell system is a good model for
the analysis of the functional role of M6a in MOR1 signal regulation. M6a knockout mice
(generously provided by Prof. Klaus-Armin Nave, Göttingen) are currently generated for
future analysis. The effects of M6a on MOR1 signal regulation in vivo will be investigated
in living animals.
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5.4.1 Receptor down-regulation
In the present study we showed that over-expression of M6a attenuated the
DAMGO-induced down-regulation of MOR1 in HEK293 cells. It is reasonable to
speculate that M6a decreased receptor down-regulation because it augmented receptor
recycling (Figure 4.12). The splice variants, MOR1D and MOR1E which show a more
rapid internalization compared with MOR1 and MOR1C, induce a faster receptor down-
regulation compared with MOR1 and MOR1C (Koch et al., 2001). One explanation for
this observation is that the enhanced receptor internalization of MOR1D or MOR1E also
increases receptor sorting to lysosomes for degradation whereas the strong interaction of
MOR1 with M6a directs receptors to recycling pathway, and thus decreases receptor down-
regulation. This model predicts a weaker interaction of M6a with MOR1D and MOR1E as
compared with MOR1 and MOR1C. This hypothesis could be easily tested in co-
expression studies.
5.4.2 Receptor desensitization
In the present study, we find that M6a augments both internalization and recycling of
the µ-opioid receptor. This altered trafficking has clear consequences on the desensitization
of MOR1. Thus, over-expression of M6a significantly decreased the rate of DAMGO-
induced receptor desensitization in both HEK293 cells (Figure 4.17) and primary cultured
neurons (Figure 4.22). Agonist-induced internalization of G protein-coupled receptors is a
process that can contribute to desensitization of signal transduction by a loss of functional
receptors at the plasma membrane (Law et al., 1984; Hoxie et al., 1993; Roettger et al.,
1995; Pak et al., 1996). On the other hand, internalization also contributes to functional
resensitization by promoting receptor recycling to cell surface (Ferguson et al., 1998;
Lefkowitz et al., 1998; Koch et al., 1998, 2001; Law et al., 2000a). The slower rate of
desensitization in M6a co-expressing cells is predominantly due to enhanced receptor
recycling since the recycling blocker monensin markedly enhances the DAMGO-induced
receptor desensitization in these cells (Figure 4.17). These findings confirm a series of
recent reports showing that MOR1 desensitization is controlled by receptor internalization
and recycling of internalized receptors to cell surface (Qiu et al., 2003; Beyer et al., 2004;
Koch et al., 2004, 2005). Onoprishvili and colleagues (2003) recently reported that an
enhanced internalization of MOR1 by co-expression of filamin A increases DAMGO-
mediated receptor desensitization in melanoma cells. It might be that filamin A enhances
receptor internalization without increasing receptor recycling. Consistent with this finding
is the observation that over-expression of filamin A increases the µ-opioid receptor down-
regulation (Onoprishvili et al., 2003), whereas M6a decreases receptor down-regulation in
the present studies.
Peptide agonists, such as DAMGO, and many opioid alkaloids induce rapid
endocytosis of the µ-opioid receptor in a number of cell types. By contrast, the alkaloid
drug morphine is weak in promoting receptor internalization (Arden et al., 1995; Keith et
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al., 1996, 1998; Whistler and von Zastrow, 1998; Bushell et al., 2002; Borgland et al.,
2003; Celver et al., 2004). Since receptor trafficking is an important regulator of agonist-
induced receptor desensitization, the significant differences of DAMGO- and morphine-
mediated receptor trafficking should lead to differences in receptor desensitization.
Whereas some studies have shown MOR1 desensitization by morphine (Avidor-Reiss et
al., 1995; Koch et al., 2001, 2004, 2005; Borgland et al., 2003; Beyer et al., 2004; Dang
and Williams, 2005), other reports claim that morphine is incapable of producing MOR1
desensitization (Blake et al., 1997; Whistler and von Zastrow, 1998; Zhang et al., 1998;
Whistler et al., 1999; Finn and Whistler, 2001; Alvarez et al., 2002; Bailey et al., 2003). In
our studies, we clearly found that chronic administration (4h) of morphine leads to a
significant MOR1 desensitization, which occurs at a higher rate compared with that after
DAMGO. This could be explained by the inability of morphine to induce MOR1
internalization and recycling which lead to receptor resensitization.
Phosphorylation of MOR1 by GRK2 is a necessary requirement of MOR1
internalization. Since morphine-activated MOR1 is known to be a poor substrate for
GRK2-mediated phosphorylation (Whistler and von Zastrow, 1998; Zhang et al., 1998),
morphine-mediated receptor phosphorylation might be insufficient for MOR1 receptor
internalization. Recent findings in our group have shown that morphine results in a slow
but persistent MOR1 phosphorylation at serine 375. This long-term phosphorylation causes
prolonged desensitization, since the lack of internalization and recycling prevents receptor
resensitization (Schulz et al., 2004).
An important factor influencing agonist-induced desensitization is the magnitude of
expressed receptors. For instance, a high expression level of receptors has been shown to
decrease the rate of agonist-induced receptor desensitization (Law et al., 2000a), and even
masks receptor desensitization in short-term agonist exposure since a part of functional
receptors is sufficient to produce maximal inhibition of adenylate cyclase.
In our experiments, we found a lower agonist-induced receptor desensitization than
in previous experiments reported by Koch et al. (1998, 2001), since the expression level of
MOR1 was 3-fold higher than in their experiments.
5.5 Molecular basis of opiate tolerance
Despite considerable progresses, the molecular and cellular mechanisms responsible
for the development of opiate tolerance are incompletely understood (see reviews in
Kieffer and Evans, 2002; Zuo, 2005). The classical hypothesis is that desensitization and
internalization of the µ-opioid receptor contribute directly to tolerance by decreasing the
number of functional surface receptors (see Kieffer and Evans, 2002 for a review). In
contrast to this hypothesis, recent studies including that from our group have well
demonstrated that agonist-induced µ-opioid receptor internalization plays an important role
in reducing the development of opiate tolerance (Koch et al., 1998, 2001, 2004, 2005;
Whistler et al., 1999; Finn and Whistler, 2001; Williams et al., 2001). Furthermore, it has
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been reported that increased µ-opioid receptor endocytosis in response to morphine
reduces the development of opiate tolerance in an animal model (He et al., 2002; He and
Whistler, 2005).
Figure 5.2. A hypothesis for opiate tolerance. In the presence of “internalizing” opioids, exemplified
by DAMGO, signaling is continued rather than rapidly terminated because of receptor resensitization.
Downstream adaptations, therefore, are limited by receptor recycling. In contrast, a “non-internalizing”
opioid such as morphine is unable to efficiently trigger receptor resensitization, and thus leads to
receptor desensitization finally. Tolerance develops from attenuated or terminated receptor signaling.
The empty µ-opioid receptor is shown as a circle; while DAMGO- and morphine- bound receptors are
schematized as a square and a diamond, respectively. Events unlikely to occur are indicated in gray.
Though it is clear that internalization of opioid receptors reduces the development of
opiate tolerance, the mechanisms whereby this occurs are still controversially discussed.
The RAVE (receptor activity versus endocytosis) model suggested that abnormally
maintained signaling in the presence of non-internalizing agonists (e.g. morphine) leads to
the development of opiate tolerance, whereas interrupted receptor signaling by receptor
internalization attenuates opiate tolerance (Whistler et al., 1999; Kieffer and Evans, 2002).
However, there are increasing evidences for an alternative model in which internalization
followed by recycling continuously resensitizes the receptors and thus counteracts
desensitization. For instance a recent publication demonstrated that the endocytotic
efficacies of opioids are negatively correlated with the development of receptor
desensitization (Koch et al., 2005). In line with this study, our experiments show 
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agonist-induced MOR1 trafficking prolongs receptor signaling by augmenting receptor
resensitization. As depicted in Figure 5.2, in our hypothesis, receptor uncoupling is
mediated predominantly by phosphorylation, and internalization is the only way in which
the µ-opioid receptor can be dephosphorylated and then resensitized. Agonists (e.g.
morphine), which promote receptor phosphorylation but not receptor internalization, cause
prolonged desensitization and signaling attenuation of opioid receptors. The attenuated
signaling contributes to the development of opiate tolerance.
In summary, in cells co-expressing MOR1 and M6a, the attenuation of DAMGO-
mediated receptor desensitization results from augmented receptor internalization and
recycling by interaction with M6a. Morphine leads to a faster receptor desensitization after
prolonged agonist exposure than DAMGO, since morphine is incapable to induce receptor
trafficking. Furthermore, in the presence of the recycling inhibitor monensin, the
internalizing agonist DAMGO induces rapid receptor desensitization whereas the non-
internalizing agonist morphine does not. These results provide evidences that the
trafficking of the µ-opioid receptor is negatively correlated with the development of
agonist-induced receptor desensitization. Receptor desensitization is crucially important in
opioid pharmacology, since it contributes to the development of opiate tolerance (Yu et al.,
1997; Polakiewicz et al., 1998; Whistler et al., 1999; Bohn et al., 1999, 2000; Fin and
Whistler, 2001; He et al., 2002; Koch et al., 1998, 2001, 2004, 2005). We therefore
hypothesize that the interaction between MOR1 and M6a attenuates the development of
opiate tolerance since M6a-enhanced receptor trafficking decreases receptor
desensitization and prolongs receptor signaling.
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6 Summary
Opiates such as morphine are still the best analgesic choice in the treatment of chronic
and serious pain. The clinical utility of opiates is limited by adaptive changes in the
nervous system occurring after prolonged or repeated drug administration. These
adaptations are believed to contribute to physiological tolerance and dependence to opiates.
All of these adaptive changes are initiated by the binding of opiate drugs to opioid
receptors that are also activated by endogenous opioid neuropeptides. The µ-opioid
receptor (MOR1) is of primary importance for mediating analgesic and addictive effects of
clinically important opiate drugs. Understanding the mechanisms of MOR1 regulation is a
key step to develop drugs and/or therapy, which result in effective analgesia without the
detrimental adaptive responses.
There is increasing evidence that receptor-associated proteins modulate the signal
transduction of MOR1. Several proteins which interact with MOR1 including the
membrane glycoprotein M6a (M6a) were previously identified by our group using a yeast
two-hybrid assay. To confirm the protein-protein interactions in mammalian cells, the
proteins were tagged with bioluminescent/fluorescent epitopes and their interactions were
assayed by a bioluminescence resonance energy transfer (BRET) technique. Of all proteins
investigated, M6a showed the strongest interaction with MOR1. This interaction was also
confirmed by co-immunoprecipitation experiments. Furthermore, the transmembrane
domains of MOR1 and M6a that are important for the interaction were characterized. In
addition, we demonstrated the interaction of M6a with a number of GPCRs, suggesting
that M6a might play a general role in the regulation of GPCRs.
M6a is a member of the proteolipid protein (PLP)/DM20 family of unclear function.
Double in situ hybridization showed a widespread co-expression between MOR1 and M6a
in many regions of rat brain. In addition, in transfected HEK293 cells, MOR1 co-
internalizes with M6a, and then co-recycles to cell surface by recycling endosomes. This is
associated with an augmented internalization and recycling of the µ-opioid receptor. In
HEK293 cells, a physiological role of endogenous M6a in MOR1 internalization was
revealed since over-expression of M6a dominant negative mutants prevents agonist-
mediated endocytosis of MOR1. In addition, by enhancing receptor recycling M6a
decreases receptor degradation in lysosomes, consistent with the observed decrease in
down-regulation of MOR1. M6a also binds to and co-internalizes with the d-opioid
receptor (DOR1). The interaction between DOR1 and M6a directs receptor post-
endocytotic sorting into recycling pathway, which further provides support for a role of
M6a in receptor recycling.
M6a-augmented MOR1 trafficking results in decreased receptor desensitization.
Importantly, while the functional property of M6a on the trafficking and signal regulation
of the µ-opioid receptor has been established in HEK293 cells, our studies in primary
cultured neurons suggest a similar function also in native neurons.
Taken together, M6a might function as an adaptor protein in receptor trafficking, and
be involved in reducing the development of opiate tolerance. Therefore, our work revealed
a new function of the PLP/DM20 glycoprotein family other than its structural role in
myelination.
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11 Zusammenfassung
Opiate wie Morphin sind nach wie vor das Mittel der Wahl bei der Behandlung von starken
und chronischen Schmerzen. Der klinische Einsatz der Opiate wird jedoch durch adaptative
Veränderungen des Nervensystems eingeschränkt, die nach langer oder wiederholter Opiatgabe
auftreten können und zur physiologischen Toleranz und Abhängigkeit gegenüber Opiaten
beitragen. Diese adaptiven Veränderungen werden durch die Bindung von endogenen wie auch
exogenen Opiaten an den Opiatrezeptor ausgelöst. Der µ-Opioidrezeptor (MOR1) ist von
besonderer Bedeutung für die Vermittlung der analgetischen und adaptiven Effekte von klinisch
relevanten Opiaten. Die Aufklärung der Mechanismen, welche an der Regulation der µ-
Opioidrezeptoraktivität beteiligt sind, ist möglicherweise der Schlüsselschritt zur Entwicklung
neuer Drogen oder veränderter analgetischer Therapien.
In der letzten Zeit mehren sich die Hinweise, dass die Signaltransduktion des µ-
Opioidrezeptors durch verschiedene rezeptor-assoziierte Proteine moduliert werden kann. In
Vorarbeiten wurden mit Hilfe der Yeast-Two-Hybrid Technik bereits verschiedene µ-
opioidrezeptor-interagierende Proteine von unserer Arbeitsgruppe identifiziert, zu denen auch das
membranständige Glykoprotein M6a (M6a) gehört. Um die Interaktion dieser Proteine mit dem
MOR1 in Säugerzellen zu bestätigen, wurden die zu untersuchenden Proteine mit
Biolumineszens/Fluoreszens-Epitopen markiert und mittels Bioluminszens-Resonanz-Energie-
Transfer Technik (BRET) untersucht. Von allen untersuchten Proteinen zeigte das M6a die stärkste
Interaktion mit dem µ-Opioidrezeptor. Diese Interaktion konnte auch mit Hilfe der
Koimmunopräzipitations-Technik immuncytochemisch nachgewiesen werden. Weitere
Untersuchungen zeigten, dass die Transmembrandomänen des MOR1 und des M6a für die Protein-
Protein-Interaktion wichtig sind. Zusätzlich konnte gezeigt werden, dass das M6a mit einer Reihe
weiterer G-Protein-gekoppelter Rezeptoren (GPCRs) interagieren kann, was auf eine
möglicherweise wichtige Funktion des M6a bei der Regulation dieser Rezeptoren hindeutet.
Das M6a-Protein, dessen Funktion bei Beginn dieser Studie noch unklar war, gehört zur
Familie der Proteolipid-Protein (PLP)/DM20 Familie. Doppel-in situ Hybridisierungen zeigten eine
Koexpression von MOR1 und M6a in vielen Hirnregionen, was eine Interaktion dieser Proteine
auch unter in vivo Bedingungen möglich macht. Im Weiteren konnte gezeigt werden, dass MOR1
und M6a in transfizierten HEK293 Zellen kointernalisieren und mittels Recycling-Endosomen
gemeinsam zur Zellmembran zurücktransportiert werden. Zusätzlich führt die Interaktion mit dem
M6a Protein zu einer Verstärkung der Internalisierung und Rezyklisierung des µ-Opioidrezeptors.
In HEK293 Zellen konnte ebenfalls gezeigt werden, dass das endogen exprimierte M6a Protein
eine wichtige physiologische Funktion bei der MOR1 Internalsierung besitzt, da die
Überexpression einer dominant-negativen M6a Mutante die agonisten-vermittelte Internalisierung
des MOR1 verhinderte. Zusätzlich konnte gezeigt werden, dass das M6a die Herunterregulation des
MOR1 vermindert, was auf die M6a-induzierte verstärkte Rezeptorrezyklisierung zurückgeführt
werden kann. M6a bindet und kointernalisiert auch mit dem d-Opioidrezeptor (DOR1). Die
Interaktion des DOR1 mit M6a führt, ähnlich wie beim MOR1, zu einer Verstärkung der
Rezeptorrezyklisierung, was ebenfalls für eine Rolle des M6a bei der Rezeptorrezyklisiserung
spricht.
Der verstärkte intrazelluläre Transport des MOR1 führt nachweislich zu einer verzögerten
Rezeptordesensitisierung. Die genannten funktionellen Eigenschaften des M6a Proteins auf den
intrazellulären Transport und die Signaltransduktion des µ-Opioidrezeptors wurden in
überexprimierenden HEK293 Zellen, aber auch in primären kultivierten Neuronen nachgewiesen.
Zusammengefasst konnten wir zeigen, dass das M6a eine wichtige Funktion als
Adapterprotein bei dem intrazellulären µ-Opioidrezeptortransport übernimmt und an der
Verminderung der Entwicklung einer Opiattoleranz beteiligt ist. Somit zeigt unsere Arbeit, dass die
Familie der PLP/DM20 Glycoproteine neben ihrer strukturellen Rolle bei der Myelinisierung auch
eine neue Funktion bei der Regulation der Aktivität von GPCRs übernehmen kann.
